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The Policy Research Unit in Economic Evaluation of Health and Care interventions is funded by the 
Department of Health Policy Research Programme. It is a collaboration between researchers from 
the University of Sheffield and the University of York.  
 
 
The Department of Health's Policy Research Unit in Economic Evaluation of Health and Care 
Interventions is a 7 year programme of work that started in January 2011.  The unit is led by 
Professor John Brazier (Director, University of Sheffield) and Professor Mark Sculpher (Deputy 
Director, University of York) with the aim of assisting policy makers in the Department of Health to 
improve the allocation of resources in health and social care. 
 
This is an independent report commissioned and funded by the Policy Research Programme in the 
Department of Health. The views expressed are not necessarily those of the Department. 
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Acronyms 
 
Acronym Definition 
ADA American Diabetes Association 
ADDQoL audit of diabetes-dependent quality of life 
ADS Appraisal of Diabetes Scale 
AEs Adverse events 
AMSTAR Assessing the quality of systematic reviews 
ASA American Society of Anesthesiologists classification,  
BCVA Best corrected visual activity 
BMI Body mass index (kg/m
2
) 
BPI-DPN Brief Pain Inventory- Diabetic Peripheral Neuropathy 
CES-D Center for Epidemiologic Studies Depression 
CG Clinical guideline 
CHU-9D Child Health Utility 9D 
DE Data extraction 
DH Department of Health 
DHP Diabetes health profile 
DHP-1 Diabetes health profile-1 
DHP-18 Diabetes health profile-18 
DR Diabetic retinopathy 
DSC-R Diabetes Symptom Checklist  W Revised 
DSIS The Daily Sleep Interference Scale 
EASD European Association for the Study of Diabetes 
ECG Electrocardiogram 
EEPRU Policy Research Unit in Economic Evaluation of Health and Care Interventions 
EQ-5D EuroQol 5 dimensions 
EQ-5D-Y EuroQol 5 dimensions youth version 
ERG Evidence review group 
ESRD End stage renal disease 
FR Future research 
HbA1c Glycated haemoglobin 
HDL-c High-density lipoprotein concentrations 
HRQoL Health related quality of life   
HS Health states 
HTA Health technology assessment 
HUI Health Utility Index 
HUI2 Health Utility Index mark 2 
HUI3 Health Utility Index mark 3 
IV Intravenous 
LDL-c Low-density lipoprotein concentrations 
mBPI-sf DŽĚŝĮĞĚƌŝĞĨWĂŝŶ/ŶǀĞŶƚŽƌǇ-Short Form. 
MCS-12 mental component summary of the SF-12 
MDT Multi disciplinary team 
MI Myocardial infarction 
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MODY Maturity onset diabetes of the young 
NCA National Clinical Audit 
NEI-VFQ-25 National Eye Institute Visual Functioning Questionnaire 
NHS National Health Service 
NTSS-6 The Neuropathy Total Symptom Score 
PCS-12 physical component summary of the SF-12 
PDPN Painful diabetic peripheral neuropathy 
PedsQL
TM
 Paediatric quality of life inventory
TM
 
PR Potential recommendations 
PREM(s) Patient reported experience measure(s) 
PROM(s) Patient reported outcome measure(s) 
PVD Peripheral vascular disease 
QA Quality assessment 
QALYs Quality adjusted life years 
QOL-DN quality of life in diabetes neuropathy instrument 
R&D Research and development 
RCT Randomised controlled trial 
SBP Systolic blood pressure 
SD Standard deviation 
SF-6D Short form 6D 
SF-36 Short form 36 
SF-12 Short form 12 
SG Standard gamble 
SS Study selection 
STA(s) Single technology appraisal(s) 
T2DM Type 2 diabetes mellitus 
TA(s) Technology Appraisal(s) 
TC Total cholesterol 
TIA Transient ischaemic attack 
TTO Time trade off 
UK United Kingdom 
UKPDS United Kingdom Prospective Diabetes Study 
VAS Visual analogue scale 
VFQ-25 Visual Functioning Questionnaire 25 
WP Work package 
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1. BACKGROUND 
The Policy Research Unit in Economic Evaluation of Health and Care Interventions (EEPRU) was 
approached by Jason Cox (Research and Development (R&D) Division) to prepare a programme of 
research to support the appropriateness of, and use of, patient reported outcome measures 
(PROMs) collected for the National Clinical Audit (NCA).  The EEPRU programme was informed by a 
R&D template prepared by Simon Bennett, Steve Fairman and Keith Willett at National Health 
Service (NHS) England. 
 
The purpose of introducing PROMs into the NCA programme is to be able to 1) compare 
performance between providers and commissioners in the NHS, 2) compare the cost-effectiveness 
of alternative providers in delivering the specific services (i.e. linking outcomes and resource use), 
and 3) assess the cost-effectiveness of alternative interventions and other changes in the NHS.  The 
intention is to introduce PROMs across a range of conditions over the next 3 years commencing with 
13 conditions in the 2014/15 NCA programme.  
 
The agreed research programme consists of 3 concurrent work packages (WP) as described in the 
document submitted to the Department of Health (DH) (8
th
 November 2013).  The current document 
provides details on the objectives, methodology and results for Work Package 1 (WP1): to determine 
what PROMs should be used in the 13 health conditions specified in the 2014/15 NCA programme. 
 
2. OVERVIEW 
WP1 is split into three separate components consisting of: 
WP1.1 To examine whether the EuroQol-5D (EQ-5D) is appropriate in the 13 health conditions 
specified in the 2013/14 NCA programme.  
WP1.2 To identify what measure could be used when the EQ-5D is not appropriate in the 13 health 
conditions, taking into account that the proposed measure would be used to generate 
preference-based utility measures (either directly through existing preference-based weights, 
or indirectly through existing mapping functions suitable for the proposed measure). 
WP1.3 To identify the evidence required to address questions of cost-effectiveness using the NCA 
data. 
 
This Appendix provides the results for diabetes and should be read in conjunction with both the 
main report and the method/search strategy appendices. 
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3. METHOD 
The full detailed methodology used is provided in Appendix A and B, including the search strategy, 
selection criteria for studies included, and data extraction etc.  In summary, a review of the literature 
was undertaken to assess the appropriateness of the EQ-5D in terms of classic psychometric criteria 
(WP1.1); where the EQ-5D was not considered appropriate, additional searches were undertaken to 
identify alternative measures (WP1.2); and finally, existing health technology assessments were 
reviewed and data requirements were compared with variables currently collected in the diabetes 
audit (WP1.3).   
 
3.1 Psychometric properties (WP1.1) 
Assessments reported in the included studies were categorised according to the following 
definitions: 
 
Acceptability 
Data relating to how acceptable the measure was to the person completing it, expressed as the 
proportion of completed surveys, or the proportion of missing data. 
 
Reliability 
There are two main definitions for reliability, a) the degree to which a measure reproduces the same 
results in an unchanged population and b) the degree to which a measure reproduces the same 
results when completed by different assessors (e.g. patient and proxy report). In both cases, 
reliability can be assessed by re-testing, and calculating the correlations or difference between tests. 
In case a) the comparison may be between the same populations separated by time, where no 
change in health state was observed (as compared to using an alternative condition specific or 
generic measure). In case b) the measure may be completed by multiple people (proxies) on the 
ƉĂƚŝĞŶƚ ?Ɛ ďĞŚĂůĨ ĂŶĚ ƚŚĞŝƌ ƌĞƐƉŽŶƐĞƐ ĐŽŵƉĂƌĞĚ ǁŝƚŚ ƚŚŽƐĞ ŽĨ ƚŚĞ ƉĂƚŝĞŶƚ ? there the outcome 
measure is specifically designed for self-report by patients, this test of reliability may be expected to 
produce less agreement.  
 
Construct validity 
This is an assessment of how well an instrument measures what it intends to measure. Two main 
definitions are used in this review.  
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a) Known group validity, where estimates for groups that are known to differ in a concept of interest 
are compared either qualitatively or statistically. The known groups may be defined using other 
measures, according to clinical categorisation.  
b) Convergent validity assesses the extent to which a measure correlates with other measures of the 
same or similar concepts. Correlation coefficients were considered low if <0.3, moderate if between 
0.3 and 0.5, and strong when >0.5.  
 
Responsiveness 
a) Change over time. This is an assessment of whether measurements using the instrument can 
detect a change over time, where a change is expected. This may be before and after an 
intervention, or through progression of a disease. Evidence was considered to be good where a t-
test was significant, though weaker evidence to support responsiveness was considered where there 
was a change in the expected direction, but was not statistically significant or not tested. Effect size 
and standardised response mean were also acceptable assessments of responsiveness.  
b) Ceiling and floor effects were also considered to be indicators of responsiveness. Assessments of 
ceiling effects include the proportion of patients who score full health within a group of patients 
with known health detriments. A ceiling or floor effect can affect the sensitivity of the measure in 
detecting changes over time in patients at the extremes of the measure (for example those with 
severe disease activity and those with just minor symptoms of the condition). 
 
3.2 Alternative measures (WP1.2) 
Where the EQ-5D was considered appropriate, no further searches were performed.  
 
3.3 Evidence required for economic evaluations (WP1.3) 
The existing Health Technology Assessments (HTAs) were reviewed alongside the variables currently 
collected in the NCA to determine if clinical or PROM data routinely collected in the NCAs would 
suffice to address questions of cost-effectiveness, and to identify any gaps in the evidence that 
would be required to compare providers, or the cost-effectiveness of interventions or policies. 
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4. RESULTS FOR DIABETES 
4.1 Evidence of appropriatness of EQ-5D in diabetes (WP1.1) 
4.1.1 Selection of systematic review 
One systematic review was identified through expert sources,(1) and two (2;3) from the Longworth 
et al. review.(4)  The process of selection of the most appropriate review is documented in Table 1.  
Janssen et al. was selected as it provides more detail about the psychometric properties of the EQ-
5D, and is also marginally more recent than the Oxford review.(1) 
 
Table 1: Selection of most appropriate review for diabetes  
Review Search date Relevance of 
review 
Quality of 
search 
Quality of 
review 
Selection 
Oxford 
(2009)(1) 
September 
2008 
Question 
relevant, but 
too little 
psychometric 
data provided 
Reliance on pre-
existing 
database, 
pubmed 
strategy not 
provided. 
However, 
probably 
adequate. 
No QA; no 
search 
numbers; single 
reviewer DE 
and SS; 
synthesis 
involved two 
reviewers 
Exclude  W less 
recent than 
Janssen, less DE 
detail than 
Janssen 
Janssen et al 
2011(2) 
January 2009 Question 
relevant, some 
detail provided 
Searched 
pubmed and 
EMBASE. Good 
supplemental 
searches. 
No QA; details 
of search 
numbers 
provided; 
unclear 
reviewers SS, 
unclear DE; 
synthesis 
unclear 
Include  W more 
recent than 
Oxford review, 
more detail 
provided 
Speight et al 
2009(3) 
Not Assessed Not a 
psychometric 
study 
Not Assessed Not Assessed Exclude  W 
question not 
relevant 
QA, quality assessment; DE, data extraction; SS, study selection. 
 
 
4.1.2 Structured abstract for Janssen et al 2011(2) 
Purpose of review 
Amongst other objectives that are not relevant to WP1.1, Janssen et al. (2011) aimed to  “ƌĞǀŝĞǁ the 
scientific evidence on the measurement performance of the EQ-5D in the assessment of health 
realted quality of life (HRQoL) in adults with Type 2 diabetes (T2DM), with a focus on the ability of 
the EQ-5D to distinguish between different complications and levels of ƐĞǀĞƌŝƚǇ ? ?
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Methods of review 
Search and study selection: EMBASE and MEDLINE (database host platform used was unclear), the 
EuroQoL website, and the research databases of the International Diabetes Federation (IDF), 
American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) 
ǁĞƌĞƐĞĂƌĐŚĞĚ ?ZĞĨĞƌĞŶĐĞůŝƐƚƐĂŶĚĂƵƚŚŽƌ ?ƐƉĞƌƐŽŶĂůĐŽůůĞĐƚŝŽŶƐǁĞƌĞƐĞĂƌĐŚĞd.  Electronic searches 
were conducted from  ? ? ? ? ƚŽ :ĂŶƵĂƌǇ  ? ? ? ? ? ƵƐŝŶŐ ƚĞƌŵƐ ĨŽƌ  ‘Y- ? ? ĐŽŵďŝŶĞĚ ǁŝƚŚ  ‘ĚŝĂďĞƚ ? ? Žƌ
specific diabetic complications in EMBASE and MEDLINE. However, the full search strategies were 
not reported and terms used in the research database searches were not given. Studies were 
selected for inclusion if they reported EQ-5D measurement properties or scores on the EQ-5D index, 
visual analogue scale (VAS) or percentage dimension scores, or the relative impacts on utilities (e.g. 
beta coefficients) of specific complications. 
 
Data extraction and synthesis: Data was extracted (unclear whether double data extraction or data 
checking performed) using a previously developed and tested standardised form. A narrative 
synthesis was performed according to the psychometric quality assessed, namely validity, reliability 
and responsiveness. These qualities were defined as a) convergent validity, the degree to which 
theoretically related measures agree; b) discriminant validity, the degree to which theoretically 
unrelated measures do not agree (this property is not considered as a separate form of validity in 
WP1, but may be included in convergent validity where reported); c) known group validity, a form of 
construct validity where groups known to vary in health level are shown to vary by the measure; d) 
ĚŝƐĐƌŝŵŝŶĂƚŝǀĞ ǀĂůŝĚŝƚǇ ? ĚĞƐĐƌŝďĞĚ ĂƐ Ă  “ƉƌĞƌĞƋƵŝƐŝƚĞ ? ƚŽĐŽŶƐƚƌƵĐƚ ǀĂůŝĚŝƚǇ ? ǁŚĞƌĞ ƚŚĞ ŵĞĂƐƵƌĞ ŝƐ
shown to distinguish between levels of health within or between patients (considered as equivalent 
to known group or convergent validity, as defined in WP1); and e) responsiveness, the ability of the 
measure to detect clinically meaningful changes over time.  
 
Results of the review   
Janssen et al. (2011) included 39 articles which presented evidence on the measurement properties 
of the EQ-5D in T2DM. The narrative synthesis was brief, and the tabulation of study results was not 
detailed. Convergent and discriminant validity (a & d) were reported in 14 studies, which mostly 
examined the strength of correlation between the EQ-5D and other generic health status measures 
or disease-specific measures. Construct validity (c) was reported in 16 studies. These mainly used 
regression and ANOVA techniques. Most demographic and clinical categories were discriminated 
between by the EQ-5D, with the exception of patients with multiple conditions and in patients with 
mild disease. A ceiling effect was noted in several studies in comparison to the short form -6D (SF-
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6D). Additional properties not listed in the methods section of the review were described in the 
narrative, namely predictive validity (not relevant to this review), responsiveness, and reliability. The 
EQ-5D was shown to be responsive in studies that assessed this, with the exception of one study 
investigating diabetic peripheral neuropathic pain. Reliability was reported in two studies as being 
 “ŐŽŽĚ ?Žƌ “ĞǆĐĞůůĞŶƚ ?ƵƐŝŶŐƚŚĞŬƐƚĂƚŝƐƚŝĐĂŶĚŝŶƚƌĂĐůĂƐƐĐŽƌƌĞůĂƚŝŽŶĐŽĞĨĨŝĐŝĞŶƚƐ (ICC).  
 
ZĞǀŝĞǁĂƵƚŚŽƌƐ ?ĐŽŶĐůƵƐŝŽŶƐ 
The review authors concluded that evidence supported construct, convergent and discriminant 
validity, test Wretest reliability and responsiveness of the EQ-5D in T2DM. However, they also noted 
that a ceiling effect and an inability to capture health detriments due to multiple complications were 
observed in several studies. 
 
4.1.3  Assessment of review in relation to objectives of work package 1.1 
Relevance of review question: One of the aims of Janssen 2011(2) is convergent with the aims of 
WP1.1.  
 
Assessment of review quality: Janssen et al. (2011) scored poorly against the relevant AMSTAR 
criteria (Table A1, Appendix). The authors did not provide a reference to a published protocol to 
evidence an a priori design, meaning the study is potentially open to bias in terms of changes to the 
analysis plan in response to the results found. No quality assessment of the included studies was 
conducted, and it was therefore not possible to formulate conclusions which take the quality of the 
included studies into account. It does not appear that double data extraction or data-checking took 
place, leaving the study at higher risk of errors. There appears to have been more than one reviewer 
involved in study selection, but it is not clear if this constituted double-checking of study selection or 
just division of labour. As such, there is a small risk that some studies may have been missed in study 
selection. The meta-analysis conducted is not of relevance to the aims of WP1.1. In addition, 
theselection criteria are poorly defined. 
 
Acceptability of the search: In addition to searching relevant electronic bibliographic databases, the 
review authors also searched several professional organization websites and performed reference 
list checking. Even though full strategies were not given, the search approach is considered adequate 
for the review. 
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Acceptability of study selection: Study selection criteria were not well defined, and reference to the 
full text of included articles (to retrieve additional data) revealed that studies had been included 
which would not have met our selection criteria. 
 
Adequacy of available data and synthesis:  The review only provided a small amount of data relating 
to each study, and this was not adequate for the requirements of WP1.1. Not enough detail was 
provided for some of the studies to enable a judgement to be made about whether the evidence 
supported the conclusions. The synthesis was very brief. 
 
In conclusion, the methods employed in the review required some remedial action. Whilst the 
searches were thought to be adequate, the inclusion criteria appeared to be wider than that of 
WP1.1. In addition, the data extraction and synthesis were not detailed enough to allow a thorough 
understanding of the psychometric properties of the EQ-5D in this population. As such, all studies 
were re-considered for inclusion, and a detailed data extraction and synthesis of these studies 
performed.  
 
4.1.4 Reanalysis of Janssen et al. 2011(2) 
Of the 39 studies initially included in the review, 16 met the inclusion criteria of WP1.1.(6-22) Study 
characteristics and results are provided in Tables A2 to A8, Appendix.  
 
In brief, one study used the USA EQ-5D tariff,(10) 13 studies used the UK EQ-5D tariff,(6-9;11;13;15-
17;19-22) of which four (8;9;11;20) were also conducted in the UK, the remainder being conducted 
in Europe in four cases,(6;7;15;16) Australia in one case, (17) Thailand in one case,(22) Singapore in 
one case(142) and multinational in two cases.(6;13)  The tariff used was not clear in Gore et al. 2005 
(set in USA),(12) and no tariff was used in Vernon et al. 2008 (unclear setting).(14) 
 
Patient characteristics differed somewhat across studies. Broad inclusion criteria were used in most 
studies, with the exception of Glasziou et al.(17) who recruited normotensive patients, four studies 
which recruited patients with painful neuropathy,(12-14;16) and one study which recruited patients 
with diabetic retinopathy.(9) Mean ages were similar across studies, ranging from 52(21) to 69(19) 
years old. The number of withdrawals was very poorly reported, with most studies only reporting 
responders. Three studies were post hoc analyses of randomised controlled trials (RCTs),(6;13;14) 
one study was a time series,(19) whilst the remainder were cross sectional studies. Only one study 
cited the measurement of psychometric properties of EQ-5D as their main aim.(10) 
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Acceptability: It was difficult to assess the acceptability of the EQ-5D as the majority of samples used 
in the studies appear to be from respondents who completed the full set of variables tested. 
However, one study did report that of the participants who completed the questionnaire (which 
comprised several measures including the EQ-5D), none of the EQ-5D items were left unanswered, 
indicating that the EQ-5D is acceptable.(8) 
 
Reliability: Two studies assessed reliability (Table A7, Appendix).(20;22) Clarke et al. reported K 
statistics ranging from 0.59 (95% confidence interval (CI) =0.45 W0.74) for the EQ-5D mobility 
dimension to 0.26 (95% CI =0.11 W0.40) for the EQ-5D pain dimension, with a good ICC of 0.59 (95% 
CI 0.41 to 0.72) for the tariff scores.(20) Sakthong et al. also reported a good correlation (r=0.74, 
95% CI 0.57 to 0.84, p<0.001).(22) Both studies suggest reliability is good (Appendix).(22)   
 
Construct validity (known group): Nine studies reported known group validity for the EQ-5D in 
people with diabetes (Table A5, Appendix).(9;11-13;15-17;22;23)  Matza et al. compared the mean 
EQ-5D for various dichotomised known groups. These groups included the median split for two 
disease-specific tools (the appraisal of diabetes scale (ADS); the diabetes symptom checklist  W 
revised (DSC-r)), whether patients wanted to lose weight, or wanted to stay the same weight; 
whether patients had daytime hypoglycaemia; whether they had night-time hypoglycaemia; 
whether they had any hyperglycaemia; whether they were treated with oral medication or injected 
insulin. The mean EQ-5D was significantly different between groups in all cases by t-test, except for 
presence of hyperglycaemia or type of treatment. Matza et al. concluded that whilst the EQ-5D is 
valid, it should not be used as the sole measure in a clinical trial.(23)  
 
In Vexiau et al. 2008, all EQ-5D health dimensions scores showed differences between those with 
and without hypoglycaemia symptoms, although the differences were only statistically significant for 
pain/discomfort and anxiety/depression (p<0.005). There was also a statistically significant 
difference between mean EQ-5D index scores between these two groups (0.70 (SD 0.26) vs. 0.80 (SD 
0.23) respectively, p<0.0005). Glasziou et al. 2007 presented graphs that showed the mean EQ-5D 
deficit at baseline was significant for those with (compared to those without) stroke/transient 
ischaemic attack (TIA); peripheral revascularisation/amputation; myocardial infarction (MI); hospital 
admission for unstable angina; currently treated hypertension, but the deficit was not significant for 
those with diabetic eye disease, or coronary artery bypass graft. Similar graphs were shown for the 
SF-6D (short form 12 (SF-12)) and SF-6D (short form-36 (SF-36)), with a similar pattern of sensitivity 
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across the classes. In addition, these latter two measures did not produce a significant difference in 
means for those with or without MI, where the EQ-5D did. Sakthong et al.(22) compared means in 
EQ-5D index in those with and without various characteristics, and found statistically significant 
differences for neuropathy, retinopathy, nephropathy and cardiovascular disorder, but not for 
glycated hypoglycaemia (HbA1c). 
 
Known group validity of the EQ-5D for visual functioning was further assessed in one study against a 
condition specific measure (Visual Functioning Questionnaire 25 (VFQ-25)), and against a clinical 
measure (visual acuity).(9) Formal statistics were not presented, but trends in EQ-5D scores were the 
same at the upper and lower extremes of visual acuity, though middle range values were not well 
differentiated by the EQ-5D, possibly due to small sample sizes as the same problem was observed 
with the Health Utility Index-3 (HUI-3) and VFQ-25.  
 
Four studies compared neuropathic pain scales or generic pain scales to the EQ-5D. These were the 
neuropathy total symptom score-6 questionnaire (NTSS-6),(11) the quality of life in diabetes 
neuropathy instrument (QOL-DN),(11) the brief pain inventory modified for pain in diabetic 
peripheral neuropathy (BPI-DPN),(12) and the modified brief pain inventory short form (mBPI-
sf)(13;16). Three studies recruited only patients with neuropathic pain,(12;13;16) whilst one 
recruited anyone with diabetes.(11) All found good agreement, which supported the EQ- ? ?ƐĂďŝůŝƚǇ
to detect pain related to diabetic neuropathy, even in a general sample of patients with diabetes. 
 
Construct validity (convergent):  Seven studies considered convergent validity of the EQ-5D 
compared to a variety of other measures (Table A6, Appendix).(6-8;14;17;21;22)  Convergent validity 
between the EQ-5D index and the WHO Diabetes treatment satisfaction questionnaire (WHO-DTSQ) 
was low in the study that assessed treatment satisfaction (r=0.28 p<0.0001).(7) The EQ-5D does not 
have an item related to treatment satisfaction, so this is perhaps not surprising.  
 
Two studies compared EQ-5D against a general diabetes scale. One study used two such scales: the 
appraisal of diabetes scale (ADS) and the diabetes symptom checklist- revised (DSC-R).(24) The study 
found moderate to strong agreement (r range: -0.44 to -0.61 (all p<0.001)), except for the 
ophthalmic scale of the DSC-R, which had only low agreement (r=-0.22, p<0.05). The second study 
used the audit of diabetes-dependent quality of life (ADDQoL),(21) and showed a strong correlation 
 ?ƐƉĞĂƌŵĂŶ ?ƐƌĂŶŬA? ? ? ? ? ?ďĞƚǁĞĞŶƚŚĞY-5D index score and the scores of those who scored well on 
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the ADDQoL for the items relating to current QoL (rather than items relating to overall impact of 
diabetes on life domains).  
 
The EQ-5D was compared against the daily sleep interference score (DSIS) in one study(14) which 
recruited only those with painful peripheral neuropathy. This study reported low to moderate 
agreement (r range: 0.08 to 0.44) for the EQ-5D, with moderate correlation only being observed in 
the pain/discomfort dimension, suggesting that the impact of painful neuropathy on sleep was not 
captured in the EQ-5D. 
 
The correlation of the EQ-5D with HbA1c was assessed by two studies.(6;22)  Sakthong et al. reported 
a low ďƵƚƐŝŐŶŝĨŝĐĂŶƚĐŽƌƌĞůĂƚŝŽŶ ?ƐƉĞĂƌŵĂŶ ?ƐƌĂŶŬƌA?-0.17, p<0.01) between the EQ-5D and HbA1c at 
baseline.(22) In Bech et al. changes in the HbA1c did not have a significant correlation with changes in 
the EQ-5D in response to treatment.(6) Both studies recruited people with T2DM with similar HbA1c 
scores at baseline (7.7% (SD 1.7, range 4.0 W15.8) vs. 7.7% (SD 1.7, range not reported) respectively).  
 
Other diabetic complications were also used in convergent validity tests. The EQ-5D was correlated 
with the SF-6D in a ranking of severity of seven complications (r=0.837 to SF-6D (SF12), and r=0.842 
to SF-6D (SF36)).(17) It was also shown to have moderate correlations with the number of 
complications (r=-0.40, p<0.01), and a measure of depression, the Center for Epidemiologic Studies -
Depression (CES-D) (-0.49, p<0.01), but low correlation with body mass index (BMI) (r=-0.15, 
p<0.01)(22)  
 
Overall, convergent validity was generally strong when compared with generic or condition-specific 
measures. There were, however, certain situations where the correlations were low. These include 
some uncertainty (owing to small sample numbers) about the ability of the EQ-5D to detect 
ophthalmic issues,(8), low or non-significant correlations with HbA1c in the two studies that reported 
this comparison, low correlations with a measure of treatment satisfaction(7) and low correlations 
with BMI in two studies.(8;22)  On balance, results suggest a lack of responsiveness of the EQ-5D to 
changes in HbA1c, rather than a complete lack of correlation.(6)  There were also lower correlations 
with the daily sleep interference scale (DSIS)(14) and with a measure of treatment satisfaction in 
diabetes (WHO-DTSQ).(7) 
  
Responsiveness (change over time): Two studies assessed responsiveness through changes over 
time (Table A8, Appendix).  Bech et al.(6) reported that the EQ-5D showed little or no change, as 
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expected, over a four month period, although the WHO-DTSQ did. Johnson et al.(19) recorded mean 
EQ-5D values each year over three years. They reported the expected decreases in EQ-5D mean 
scores over time (within subject effects analysis for time and diabetes status:  f=4.49 p=0.012), 
supporting the responsiveness of the EQ-5D.  
 
Responsiveness (ceiling effects): Three studies assessed responsiveness through examining 
potential ceiling effects on the EQ-5D (Table A8, Appendix).(8;10;21)  Matza et al. 2007 noted that 
40% of those with diabetes scored full health on the EQ-5D, whilst 0% scored full health on the 
Psychological General Well-Being Index. Similarly, Bharmal & Thomas 2006 noted that amongst 165 
people with diabetes (from a general population sample) who scored full health on the EQ-5D, the 
mean physical component summary of the SF-12 (PCS-12) was significantly different to those with 
no medical conditions, whereas the mental component summary of the SF-12 (MCS-12), and total 
score of the SF-6D were not significantly different. This indicates a ceiling effect in the EQ5D in 
comparison to the PCS-12. In Sakthong et al. 37.8% of people with diabetes reported full health, and 
of these, the mean ADDQoL was -3.4 (SD 2.49), indicating a ceiling effect of the EQ-5D in comparison 
with the ADDQoL.(22) 
 
 
4.1.5 Conclusion of appropriateness of EQ-5D in diabetes 
The evidence base used to assess the appropriateness of the EQ-5D in patients with diabetes is 
relatively large (N=16), with the majority using data obtained using the UK EQ-5D tariff, and all using 
adults samples.  Acceptability and reliability were both reported to be good.  There was some 
evidence of a ceiling effect in patients with diabetes, which may be more relevant in newly 
diagnosed patients who do not have diabetes related complications, and are thus more likely to 
score relatively high on the index. The majority of studies reported the construct validity of the EQ-
5D was good when compared to diabetes specific clinical and quality of life measures. Exceptions 
included, for example, levels of visual acuity, and potentially HbA1c. Poor correlations against some 
variables are of less concern where the comparator may not reasonably be expected to produce a 
correlation with HRQoL. For example, the relationship between HbA1C and HRQoL is complex; HbA1c 
levels are an indication of blood glucose levels over the previous 2-3 months, whereas the EQ-5D 
asks patients what their HRQoL is today.  In conclusion, the EQ-5D is adequate in patients with 
diabetes but additional research is required before it can be recommended for patients with visual 
problems (Table 2).  
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Table 2: Summary of evidence on EQ-5D for diabetes 
Measure (N) Acceptability Reliability Construct (KGV; 
Convergent) 
Responsiveness  
(Change over time; Ceiling 
effects) 
Adults 
EQ-5D (16) Good  Good  Good; Mixed Good; Poor  
 Adequate, with exception of potential problems in patients with vision problems.   
N: number of studies; KGV: known group validity 
 
4.2 Alternative measures in diabetes (WP1.2) 
Based on the psychometric properties of the EQ-5D reported for patients with diabetes, with the 
exception of potential problems in patients with vision problems, and the suggestion that there may 
be a ceiling effect, the evidence suggests the EQ-5D is appropriate in adults with diabetes.  
Consequently the evidence on other condition-specific or generic measures was not reviewed. 
 
It is worth noting, however, that the NHS outcomes framework uses the Diabetes health profile 
(DHP) self-reported outcome measure in conjunction with the EQ-5D.(5) The DHP is available in two 
forms, DHP-1 and DHP-18. DHP-18 takes less time to complete, is available in electronic formats as 
well as paper, and there is some limited evidence and ongoing research relating to its use in cost 
utility analysis.(25) It aims to capture the impact of diabetes on everyday social and emotional 
functioning, which may not be captured by other measures.  
 
The problems with the EQ-5D in vision have been noted elsewhere.(4;26) and a bolt-on for vision has 
ďĞĞŶ ĚĞǀĞůŽƉĞĚ ? WĂƚŝĞŶƚƐ ĂƌĞ ĂƐŬĞĚ ƚŽ ƐĞůĞĐƚ ďĞƚǁĞĞŶ  “/ŚĂǀĞ ŶŽ ƉƌŽďůĞŵ ƐĞĞŝŶŐ ? ?  “/ ŚĂǀĞ ƐŽŵĞ
ƉƌŽďůĞŵƐƐĞĞŝŶŐ ?ĂŶĚ “/ŚĂǀĞĞǆƚƌĞŵĞƉƌŽďůĞŵƐƐĞĞŝŶŐ ? ?dŚĞŝŵƉĂĐƚŽĨƌĞƐƉŽŶƐĞƐŽŶƚŚĞǀĂůƵĂƚŝon 
of health states has been tested in an exploratory and a full valuation study.(4) The vision bolt-on 
has been shown to significantly impact on at least some health states, with complex interplay 
between severity of the vision response, and severity of responses in the other dimensions. 
However, the authors caution that sample sizes were small, and that further research with larger 
sample sizes is required.  
 
There will be some children in the diabetes audit but it is thought that these will be in the minority 
due to the age-related prevalence of the condition.  Consequently, due to the time constraints of the 
project, the evidence base describing potential alternative PROMs for paediatrics with diabetes was 
not reviewed.   
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4.3 Evidence for economic evaluations in diabetes (WP1.3) 
4.3.1 Cost-effectiveness modelling approach used in recent HTAs in diabetes 
Ten technology appraisals (TAs) relating to diabetes were identified from the searches.  A CG was 
subsequently identified from the references lists of the included studies.(27) Two of the TAs were 
superseded by rapid reviews of the evidence,(28;29) one was withdrawn (see clinical guideline (CG) 
87),(30) and one was suspended due to licence withdrawal.(31) All the TAs were in T2DM.  The CG 
and four single technology appraisals (STAs) compared insulin therapies,(27;32-35) and the 
remaining two STAs compared interventions for diabetic related macular oedema.(36;37) One 
examined the clinical and cost-effectiveness of a pharmaceutical intervention,(28;29) while the 
other examined the clinical and cost-effectiveness of an intravitreal implant (Table 3).(28;29) 
 
The models comparing insulin therapies were generally constructed around the United Kingdom 
Prospective Diabetes Study (UKPDS), using individual patent level simulation Markov models 
comprising of discrete health states representing micro and macrovascular diabetic complications 
(Figure 1).(20)  Clinical trial data were used together with UKPDS risk functions to describe the 
clinical effects of the interventions.  UKPDS risk functions are available for congestive heart failure, 
ischaemic heart disease, myocardial infarction, stroke, blindness, ulcer, amputation, and renal 
failure.(20)  The variables required to use the functions included: HbA1c, BMI, systolic blood pressure 
(SBP), high-density lipoprotein (HDL-c), low-density lipoprotein (LDL-c), white blood cell, 
haemoglobin, heart rate, epidermal growth factor receptor, presence of micro/macro albuminuria, 
atrial fibrillation and peripheral vascular disease.  Markov models were used for both macular 
oedema interventions and the discrete health states were defined using severity grades based on 
best corrected visual activity (BCVA),(36) or visual acuity scores (Figure 2).(37) Effectiveness of the 
interventions was modelled using clinical trial data which provided evidence of changes in either 
BCVA or visual acuity scores. 
 
All studies quality adjusted survival by assigning mean utility values to the discrete health states.  
The models comparing insulin interventions used EQ-5D evidence predominantly sourced from the 
UKPDS.(20)   Exceptions were the disutilities associated with weight changes and hypoglycaemic 
events (which are not included in the UKPDS).  Conversely, the utilities used in the models 
comparing interventions for diabetic macular oedema were modelled using regressions which 
mapped from the clinical variables (BCVA, visual acuity scores) to HRQoL data (EQ-5D, non-societal 
preferences) as shown in Figure 2.(38) The blue (diamond) line and red (square) line show the 
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changes in disease severity (measured using visual acuity scores) and utilities (measured using EQ-
5D) over time respectively. 
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Figure 1:  Modelling approach used in the diabetes HTAs 
 
Legend: Orange framed boxes with uppercase text describe the health states used in the diabetes TA models while the purple framed boxes with lower case (non italic) text 
describe the evidence used.  The boxes with italised text are additional information which would ideally be collected to inform future economic models.   
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Figure 2:  Modelling utilities as a continuous measure in diabetes macular oedema  
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It was noted in several evidence review group (ERG) reports that the key areas of uncertainty in the 
models comparing insulin control were the HRQoL parameters used for hypoglycaemic events and 
treatment related changes in weight.  In the models exploring interventions for diabetes related 
visual acuity, the cost-effectiveness estimates were also noted to be sensitive to the utility values 
used.  The EQ-5D may not be sensitive to changes in sight and thus not appropriate for this condition 
(as discussed above).(4;26)  
 
Table 3: Summary of existing TAs in diabetes 
 Model approach Method used to model utilities  
STA: Diabetes (type 2) - canagliflozin; 2014(32) 
 Patient level Markov model 
Health states: complication free, chronic kidney 
disease (7 stages), neuropathy (5 conditions), 
retinopathy (4 conditions), ischemic heart disease, 
myocardial infarction, chronic heart failure, stroke, 
peripheral vascular disease, death. Additional 
variations:  weight changes (BMI), hypoglycaemic 
events (mild, moderate, severe), upper and lower 
UTIs, GMI, gastrointestinal upset (nausea) 
Effectiveness: principally driven by HbA1c, BMI, 
SBP, cholesterol (used in UKPDS functions); rates 
for AEs (hypoglycaemic events, UTI, GMI, nausea) 
and discontinuation; retinopathy   
Source: clinical RCTs (network meta-analyses) 
Utility: EQ-5D supplemented with non-preference 
data (TTO); mean values assigned to discrete HS 
Source: published literature (CODE-2 study plus 
others)
 
AEs: discrete HS utilities cover majority of these, 
additional changes in utility modelled for changes in 
BMI (statistical relationship)  
STA (TA288): Type 2 diabetes - dapagliflozin combination therapy; 2013(34) 
 Patient level DES, predominantly UKPDS 
Health states: ischemic heart disease, myocardial 
infarction, chronic heart failure, stroke, 
amputation, blindness, end stage renal disease, 
death.  Additional: weight changes, hypoglycaemic 
events 
Effectiveness: HbA1c, SBP, TC:HDL, BMI (used in 
UKPDS functions); rates for AEs (hypoglycaemic 
events, UTI, GMI, nausea) and discontinuation 
Source: clinical RCTs 
Utility: EQ-5D, HUI, supplemented with expert 
opinion; mean values assigned to discrete HS for 
macro & micro HS 
Source: published literature
 
AEs: discrete HS utilities cover majority of these, 
additional changes in utility modelled for changes 
STA(TA248: Diabetes (type 2) - exenatide (prolonged release); 2012(39) 
 Markov model  
Health states: predominantly UKPDs 
Effectiveness: HbA1c, SBP, TC:HDL (UKPDS 
functions) 
Effectiveness:  
Source: clinical RCTs 
Utility: EQ-5D, HUI, assumption; mean values 
assigned to discrete HS  
Source: published literature
 
AEs: HRQoL loss due to treatment induced nausea, 
reduced fear of hypoglycaemic episodes 
CG (CG87): Type 2 diabetes: newer agents for blood glucose control (update of CG66), 2010(27) 
 Patient level simulation (UKPDS outcomes model) 
Health states: ischemic heart disease, myocardial 
infarction, heart failure, stroke, amputation, 
blindness, renal failure, hypoglycaemic events 
Effectiveness: HbA1c, SBP, TC:HDL (UKPDS 
functions) 
Source: clinical RCTs 
Utility: EQ-5D supplemented with assumptions for 
weight change; mean values assigned to discrete HS 
Source: UKPDS (Clarke) and literature 
AEs: HRQoL change due to treatment induced weight 
change, QoL loss due to treatment induced nausea 
STA (TA203): Diabetes (type 2) - liraglutide; 2010(35) 
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 Markov model 
Health states: micro & macrovascular 
complications, hypoglycaemic events 
Effectiveness: HbA1c, SBP, TC:HDL, BMI 
Source: clinical RCTs 
Utility: EQ-5D predominantly; mean values assigned 
to discrete HS 
Source: Clarke et al UKPDS, supplemented by 
published literature 
AEs: HRQoL change due to treatment induced weight 
change, HRQoL loss due to hypoglycaemic events 
STA (TA301)
a
: Diabetic macular oedema - fluocinolone acetonide intravitreal implant; 2013(36)
 
 Markov model used to extrapolate beyond the RCT 
duration (i.e. at 3 years) 
13 discrete health states defined by 5 ETDRS bands 
of the BCVA in the treated eye, plus death 
Effectiveness: improvement in ETDRS criteria 
Source: clinical RCTs 
Utility: TTO and SG from patients with AMD; mean 
values assigned to discrete HS 
Source: TTO exercise with 72 patients with AMD 
Values are for the BCVA in the best seeing eye 
AEs: disutility due to AEs (cataract development, 
raised intraocular pressure) not modelled 
STA (TA274)
b
: Macular oedema (diabetic) - ranibizumab; 2013(36)
 
 Markov model (cohort) 
8 discrete health states defined by visual acuity 
scores (0-25; 26-35; 36-45; 46-5; 56-65; 66-75; 
76-85; 86-100 letters) plus death 
Effectiveness: change in visual acuity 
Source: clinical RCTs 
Utility: EQ-5D; regression between  visual acuity 
scores and EQ-5D; mean values assigned to discrete 
HS 
Source: published literature
 
AEs: disutility due to treatment toxicity not modelled 
HS: health states; AEs: Adverse Events; STA: Single Technology Appraisal; TA: Technology Appraisal; CG: 
Clinical Guideline; TTO: Time trade-off; SG: Standard Gamble, RCT: randomised controlled trial; BCVA: best 
corrected visual activity; AMD: age-macular degeneration; PLS: patient level simulation; GMI: genital 
mycotic infection; UTI: urinary tract infection; ETDRS: Early Treatment of Diabetic Retinopathy Study eye 
chart, DES: discrete event simulation; TC: total cholesterol; BMI: body mass index; SBP: systolic blood 
pressure; UKPDS: United Kingdom Prospective Diabetes Study; HbA1c: glycated haemoglobin; HUI; health 
utility index; CG: clinical guidelines; TC:HDL: ratio of total cholesterol to high density lipoprotein  
a 
details on modelling approach taken from TA271 as TA301 review this model and do not construct a new 
model.  
b
details on modelling approach taken from TA237 as TA274 review this model and do not construct 
a new model 
 
Diabetes is a complex disease and patients are at risk of multiple diabetes related complications.  
The existing economic evaluations described above cover just a proportion of the possible health 
states in a typical clinical pathway.  Areas not explored or modelled in detail include (for example) 
leg ulcers, erectile dysfunction, surgical interventions, annual screening for complications, day to day 
management of diabetes, management of diabetes when hospitalised for comorbidities etc.  Many 
of these may have implications in terms of comparing providers or policies.  Although not intended 
to be exhaustive, examples of the evidence required to extend the economic approach beyond what 
is explored in the existing models are provided in Figure 1 above. 
 
The following core evidence would be required to compare providers or the cost-effectiveness of 
interventions for diabetes: 
x Blood glucose control  
x Clinical variables used in the UKPDS functions (HbA1c, SBP, ratio of total cholesterol to high 
density lipoprotein (TC:HDL), BMI)  
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x Both micro and macro vascular events (e.g. ischaemic heart disease, chronic heart failure, 
renal failure, peripheral vascular disease) 
x Surgical procedures (type of intervention (e.g. revascularisation, amputation), success rate, 
post-surgical complication, length of stay etc) 
x Pharmaceutical interventions (type of intervention, concomitant medications, adverse 
events) 
x Screening uptake and results (foot, eye, etc) 
x Utility values (collected alongside condition severity and surgical interventions) 
x Death rates (diabetes related, all cause) 
 
The majority of this evidence would need to be linked through timings of collection. 
 
 
4.3.2 Fields collected in the core diabetes NCAs 
The National Diabetes Audit integrates data from both primary and secondary care sources from all 
patients (irrespective of age) diagnosed with diabetes (all types of diabetes mellitus, excluding 
gestational diabetes, impaired glucose tolerance, impaired glucose fasting) in England and Wales.  
Participation in the audit is voluntary for primary care but all trusts with specialist diabetes services 
in England and Wales are expected to participate in the audit.  It is understood that the audit is 
currently expanding to gather information on: pregnancy care in women with diabetes, and diabetes 
footcare, and these are discussed below.(40) 
 
Details of the fields in the core diabetes NCA are provided in two documents.  There are very few 
mandatory fields (NHS number, NHS organisation code, diabetes type, date of diagnosis, GP practice 
code, sex, date of birth, postcode), and records which do not collect the full complement of 
mandatory fields are rejected (Table 4).(40)  However, in the optional fields, there is an exhaustive 
list of codes for different diabetes diagnoses with and without diabetes related complications, and a 
list of fields providing clinical parameter levels such as HbA1c, cholesterol, BMI etc. (Table A9, 
Appendix).  If these can be obtained from GP patient records automatically, this increases the 
evidence available from the audit considerably. 
 
There is also a National Diabetes Inpatient Audit, which includes a Patient Experience questionnaire 
and an associated Bedside Audit form (Table A9, Appendix).  The information collected provides a 
snapshot (from a pre-ƐƉĞĐŝĨŝĞĚĚĂǇ ?ŽĨĚŝĂďĞƚĞƐŝŶƉĂƚŝĞŶƚƐ ?ƉĞƌĐĞƉƚŝŽŶƐŽĨƚŚĞŝƌĞǆƉĞƌŝĞŶĐĞƐƌĞůĂƚŝŶŐ
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to the support and services received.  The proposed objective of this audit is to use the results to 
improve inpatient experience.  The bedside audit collects information (completed by the nurse) 
ƌĞůĂƚŝŶŐ ƚŽ ƚŚĞ ƉĂƚŝĞŶƚ ?Ɛ ĚŝĂďĞƚĞƐ ƚǇƉĞ ĂŶĚ ƚƌĞĂƚŵĞŶƚ ƌĞĐĞŝǀĞĚ ?  dŚĞ ƉĂƚŝĞŶƚ ĞǆƉĞƌŝĞŶĐĞ
questionnaire (completed by the patient) collects information relating to staff seen, ability to 
provide their own diabetes care (insulin and testing of blood sugar levels), the appropriateness and 
ƚŝŵĞůŝŶĞƐƐŽĨ ƚŚĞ ĨŽŽĚƉƌŽǀŝĚĞĚĂŶĚƚŚĞƉĂƚŝĞŶƚ ?ƐƉĞƌĐĞƉƚŝŽŶŽĨ ƚŚĞĚŝĂďĞƚĞƐƌĞůĂƚĞĚƐƵƉƉŽƌƚ ĨƌŽŵ
hospital staff. 
 
Table 4: Mandatory fields collected in the core diabetes NCA  
PATIENT DEMOGRAPHIC/OBSERVATION DATA
a 
 E,^ŶƵŵďĞƌ ?ĂƚĞKĨďŝƌƚŚ ?WŽƐƚĐŽĚĞ ?ƉĂƚŝĞŶƚ ?ƐƵƐƵĂůĂĚĚƌĞƐƐ ? ?'ĞŶĚĞƌ 
PROVIDER INFORMATION
a 
 GP practice code, NHS organisation code (provider code)  
CLINICAL HISTORY
a 
 Date of diagnosis (diabetes), Diabetes type (e.g. Type 1, Type 2,  MODY, other specified, not specified) 
OBSERVATIONS
a 
  No mandatory fields  
(Multiple clinical variables in optional data e.g. BMI, BP, Cholesterol, HbA1c etc. See Appendix) 
2 CODES 
b 
  Diabetes mellitus diagnosis (plus multiple combinations of complications, e.g. DM with no complication, 
DM with hyperosmolar coma, DM with renal manifestation, DM with ophthalmic manifestation, DM with 
peripheral circulatory disorder; Insulin dependent DM with gangrene, Insulin dependent DM with 
nephropathy, Insulin dependent DM with hypoglycaemic coma, Insulin dependent DM with diabetic 
cataract, Non-insulin Insulin dependent DM with ulcer, T2DM with multiple complications etc) 
Latest diagnosis code of diabetes mellitus (multiple combinations as above) 
NHS, nation health service: GP: general practitioner; MODY: maturity onset diabetes of young; DM, diabetes 
mellitus; BMI, body mass index; BP, blood pressure; HBA1C, glycated haemoglobin; T2DM, type 2 diabetes 
mellitus 
a
National Diabetes audit CSV Specification 2012-2013 V5.0 01/05/2013; 
b
NDA Primary care extraction 
specification 2012-2013 (linked to primary care records unless patient dissents) 
 
 
4.3.3 Comparing fields in diabetes NCA with variables used in existing HTAs  
The existing HTA models comparing insulin therapies use the UKPDS risk functions to model the 
benefits of treatments in terms of reductions in both micro and macrovascular complications.  The 
key variables (HbA1c, BMI, SBP) required for the functions are noted as optional fields in the current 
core diabetes NCA (Appendix).  While many of the variables required are not currently listed, they 
may be available from GP records via the primary care audits.  However, it is not clear if a key 
variable (frequency and severity of hypoglycaemic events) is recorded anywhere. 
 
The existing HTA models comparing interventions for diabetes related visual acuity use a clinical 
grading measure (e.g. BCVA) to describe health states within the model, and changes in these to 
represent the effectiveness of the intervention.  While the optional fields contain a field relating to 
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eye screen attendance, there is no information which suggests that the results of eye screens are 
recorded in the NCA, or that presence or severity of macular oedema is recorded. 
 
No patient reported outcome measures are currently collected in the core diabetes NCA.  However, 
it is understood that there are two additional new components currently being piloted.  The Patient 
ǆƉĞƌŝĞŶĐĞ ŽĨ ŝĂďĞƚĞƐ ^ĞƌǀŝĐĞƐ ? ǁŝůů ŵĞĂƐƵƌĞ ƉĂƚŝĞŶƚƐ ?ĞǆƉĞƌŝĞŶĐĞƐ ŝŶ ƉƌŝŵĂƌǇ ĐĂƌĞ ĂŶĚ ƐƉĞĐŝĂůŝƐƚ
services (initial results due June 2014), and the National Diabetes Foot Care Audit will explore: if 
nationally recommended care structures for management of diabetic foot disease are in place, if the 
treatment of active diabetic foot disease complies with national guidance, and if the outcomes of 
diabetic foot disease are optimised (due to launch Summer 2014).  It is possible that these audits will 
enhance the existing fields with information directly relating to patient experience.  However, there 
are currently no fields relating to HRQoL or any alternative measure which could be used to generate 
the preference-based data required to inform cost-effectiveness models. 
 
While it is possible that many of the utility values required for economic evaluations will be available 
from the literature, the inclusion of a preference-based HRQoL measure (preferably the EQ-5D) in 
the diabetes audits would be useful for gaps in the evidence base such as HRQoL associated with 
hypoglyceamic events and vision.  For patients with diabetes related visual acuity, it would be 
beneficial to include a variable (such as the VFQ-25, BCVA, or visual acuity score) to grade this 
condition, and potentially the EQ-5D vision bolt-on.  The variable used should be selected on the 
basis that it could ultimately be used to weight survival to generate quality adjusted life years 
(QALYs) (for example via a mapping mechanism).  Finally, with the exception of attendance on the 
DESMOND programme, the core NCA does not include any information on interventions or 
procedures received.  However, both the current patient experience questionnaire and the diabetes 
inpatient audit contain numerous questions relating to diabetic complications, control, prescribing 
and drug management errors, intravenous insulin infusions, involvement of specialist diabetes 
teams, and general foot care, all of which would be useful information for economic evalutions. 
 
Depending on the level of responses collected in the inpatient audit, with additional fields added, it 
is possible that the diabetes NCA could be used to compare providers and the cost-effectiveness of 
interventions.  With the exception of the two additional audits currently being piloted, the existing 
diabetes inpatient audit, and the patient experience of diabetes services audit, no ongoing or 
scheduled research in the area of PROMs for the diabetes NCA are known.(40)[personal 
communication, Eleanor Bunn, Audit coordinator, 13th May, 2014] 
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4.4 Recommendations for diabetes   
In general, the EQ-5D appears to be adequate in patients with diabetes, and based on the 
ĂƐƐƵŵƉƚŝŽŶƚŚĂƚƚŚĞĂƵĚŝƚĐĂŶďĞůŝŶŬĞĚƚŽƉĂƚŝĞŶƚƐ ?ƉƌŝŵĂƌǇĐĂƌĞƌĞĐŽƌĚƐ ?ƚŚĞĐƵƌƌĞŶƚdiabetes audit 
collects much of the information required to conduct economic evaluations.  The exceptions in both 
cases are in patients with visual problems, and information relating to HbA1c and hypoglycaemic 
events.  Potential recommendations (PR) and areas for future research (FR) are discussed below.  All 
suggested future research areas are indicative and would require a discussion and detailed proposal 
if required. 
 
As the NCA for diabetes covers both primary and secondary care, this will involve patients across the 
full spectrum of the condition, from newly diagnosed patients to patients with long standing 
diabetes with complications such as end stage renal disease.  While there is no suggestion that the 
EQ-5D suffers from a floor effect in this patient group, the suggested ceiling effect could be 
problematic for newly diagnosed patients with no diabetic related complications.  It is 
recommended that consideration is given to the inclusion of the EQ-5D in all the different diabetes 
audits (i.e. adapting the current ŝŶƉĂƚŝĞŶƚ ‘ƉĂƚŝĞŶƚĞǆƉĞƌŝĞŶĐĞƋƵĞƐƚŝŽŶŶĂŝƌĞ ?ĨŽƌƵƐĞŝŶƚŚĞƉƌŝŵĂƌǇ
care setting) if possible to capture HRQoL scores across the full spectrum of the condition (PR.1).  As 
mentioned in previous sections, the use of the EQ-5D-5L, could potentially reduce any ceiling effect 
in patients less severely affected by the condition.  The psychometric properties of this instrument 
would need to be assessed in patients with diabetes (FR.1). This study would require the concurrent 
collection of a measure against which the EQ-5D could be compared, together with additional 
information such as patient demographs, diabetic related complications (micro and macrovascular), 
hypoglycaemic events, clinical variables (e.g. HbA1c) and  current medications etc.  It is 
recommended that the DHP (see Section 3.2) is collected alongside the EQ-5D to capture issues 
relating to daily management of the condition (PR.11). 
 
A potential solution to possible issues in capturing changes in HRQoL in patients with vision 
problems (such as diabetes related macular oedema), might be the use of a bolt-on to the EQ-5D 
(PR.12 ? ?dŚĞ ‘ďŽůƚ-on ?ŵĞƚŚŽĚŽůŽŐǇŝŶǀŽůǀĞƐŝŶĐůƵĚŝŶŐĂƋƵĞƐƚŝŽŶƌĞůĂƚŝŶŐƚŽǀŝƐŝŽŶĂƐĂŶĂĚĚŝƚŝŽŶƚŽ
the standard five questions in the EQ-5D.  Exploratory research eliciting preferences using time 
trade-off (TTO) methods from a sample of the UK population demonstrated this methodology could 
potentially have a significant effect upon EQ-5D valuations.  However, due to limitations such as the 
relatively small sample size, the authors recommend additional research in larger samples is 
required (FR.1).(4)  On the same issue, the concurrent collection of a HRQoL measure and a clinical 
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variable such as the VFQ-25, BCVA or visual acuity score would enhance this evidence in terms of 
usefulness in future economic models (PR.2).  Some evidence exists which could potentially be used 
to link these measures to utilities, depending on which clinical measure and which preference-based 
measure was used in the audit.(41;42) 
 
As discussed previously, the DH PROMS use the DHP which captures the day to day issues relating to 
managing diabetes.  Hypoglycaemic events are a common consequence of insulin and weekly rates 
have been estimated at 0.82 and 0.33 for Type 1 and insulin-treated T2DM respectively.(43)  
Hypoglycaemic episodes can range from benign (remedied by eating fast-acting carbohydrates), to 
seizure, coma and even death.(44)  Severe or frequent hypoglycaemic events can be traumatic for 
patients with diabetes.  Preference-based HRQoL data from people who experience these events, 
and the impact on HRQoL associated with the fear of a future hypoglycaemic events are particularly 
sparse (Section 6.2).  A study using data collected in the NCA exploring these issues would add 
considerably to the existing evidence base in this area and would inform future economic models in 
the UK and wider settings (FR.3). 
 
Although in the minority, it is believed there will be some paediatrics in the diabetes audit.  As in the 
previous sections, it is recommended that consideration is given to the inclusion of paediatric 
preference-based HRQoL questionnaires (PR.4), which again would require a primary piece of 
research to assess the psychometric properties in children with diabetes (FR.4). 
 
While it is understood that the primary and secondary care audits could potentially be linked, and 
that additional detail from the GP records could be obtained, this is by no means clear.   In addition, 
it is not clear if these would suffice to provide information on variables such as HbA1c, BMI, SB, HDL-
c, LDL-c, white blood cell, haemoglobin, etc. which are the key clinical variables used in cost-
effectiveness models in diabetes.  It is also not clear if it would be possible to link these to current 
treatment.  A thorough inspection of the audit data would answer many of these queries and enable 
a more robust assessment of what would be required to perform economic evaluations with the 
current audit data (FR.5).  
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Table 5: Recommendations and associated future research for diabetes 
PR.1 Include the new version of the EQ-5D (EQ-5D-5L) and the DHP in future adult patient 
questionnaires 
FR.1 Assess the psychometric properties of the EQ-5D-5L and the DHP in adults with diabetes 
using data collected in the audit 
PR.2 Include the vision  bolt-on to the EQ-5D for patients with vision problems 
FR.2 Conduct a study to generate preference-weights for the EQ-5D vision bolt-on 
PR.3 Include a clinical measure such as the BCVA or  vision acuity score in the audit (collected at 
the same time as the HRQoL variable) 
FR.3 Conduct a study exploring the effect on HRQoL associated with hypoglycaemic events and 
the associated fear of future events using data collected in the audit 
PR.4 Include paediatric preference-based HRQoL instruments (e.g. Child Health Utility 9D (CHU-
9D) and the HUI2 or Paediatric quality of life inventory
TM
 (PedsQL)) in future paediatric 
questionnaires 
FR.4 Assess the psychometric properties of the paediatric preference-based tools in paediatrics 
with diabetes using data collected in the audit 
FR.5 Detailed analyses of fields currently collected in the diabetes audit to identify 
recommendations for future mandatory fields 
 
 
5.  SUMMARY   
5.1 Summary of evidence used to inform the conclusions for WP1.1 and WP1.2 
A reanalysis of an existing review (n=16 primary studies) provided evidence that the acceptability 
and reliability of the EQ-5D are good (Table 6). There was some evidence of ceiling effects which 
may affect responsiveness in newly diagnosed diabetics and those without complications. Construct 
validity was generally good when compared to diabetes specific and generic quality of life measures, 
with a few exceptions, most notably in vision. Problems with the EQ-5D in vision have been noted 
elsĞǁŚĞƌĞ ĂŶĚ ĂĚĚƌĞƐƐĞĚ ƚŚƌŽƵŐŚ ƚŚĞ ƉƌŽĚƵĐƚŝŽŶ ŽĨ Ă ǀŝƐŝŽŶ  “ďŽůƚ-ŽŶ ? ĨŽƌ ƚŚĞ Y-5D. It is 
recommended this is used alongside the EQ-5D. Paediatric measures were not reviewed due to time 
constraints and a low prevalence of diabetes in this population.  
 
Table 6: Summary of evidence supporting the psychometric properties of EQ-5D in all conditions 
Condition Measure N Acceptability Reliability Construct Responsiveness Overall 
 KGV Convergent Change  
over 
time 
Ceiling  
Effect 
Diabetes  EQ-5D 16 Good Good Good Mixed Good Poor Acceptable* 
Diabetes 
(daily 
management) 
DHP The recommendation is based on those in PBR [DH2013] and the psychometric 
properties of this measure have not been reviewed in the current report 
Diabetes 
(vision) 
EQ-5D vision 
bolt on 
This measure requires additional validation in a large dataset 
N: number of studies used to inform conclusions; KGV: known group validity; *Not appropriate for DM related 
vision problems, or neuropathy  
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5.2 Summary of evidence required for use in economic evaluations (WP1.3) 
The existing audit does not include a patient questionnaire.  A patient reported experience measure 
(PREM) focussed questionnaire for patients receiving secondary care is currently being piloted, 
although this is not believed to cover patients treated in primary care.  The evidence collected in this 
questionnaire will be useful when comparing providers.  There is a relatively large evidence base on 
preference-based data in patients with diabetes which could be used to inform formal economic 
models.  However, there are gaps in this evidence where data collected in the audit would be 
beneficial.  In particular, for patients with diabetes related vision conditions and to capture the 
HRQoL associated with hypoglycaemic events.   The audit collects much of the evidence required to 
conduct formal economic evaluations and if the inpatient data could be linked to GP records this 
would expand the evidence available considerably.  There would remain some issues relating to the 
timing of the data collection, but it is believed that these data could be used to inform formal 
economic evaluations.   
 
In summary, while the evidence collected in the individual audits will allow comparison of providers 
in many cases, it is clear that the mandatory fields in most of the audits will not provide sufficient 
detailed information to perform formal economic evaluations.  The main omission is the lack of 
PROMs which limits the flexibility of the data in terms of comparing either providers or interventions 
used in routine clinical practice.  However, many of the audits contain optional fields which would be 
useful for economic evaluations and enforcing the collection of key variables is recommended in 
many of the audits.  A recurrent issue relates to the level of detail collected and the timing of the 
variables collected.  To be useful for economic evaluations, many of the variables used have to be 
synchronised in terms of timing of collection, and many need to be collected over periods of time to 
assess progression or relapse etc.  An additional key issue which arises throughout many of the 
reviews is the collection of information relating to side effects of pharmaceutical interventions and 
adverse events associated with surgical procedures.  The audits could provide valuable information 
ŽŶƚŚĞƐĞƌĂƚĞƐ ?ĂŶĚƚŚĞĞĨĨĞĐƚƐƚŚĞǇŚĂǀĞŽŶƉĂƚŝĞŶƚƐ ?,ZYŽ> ?ǁŚen used and performed in routine 
clinical practice.  
 
  
31 
 
 
APPENDIX: DIABETES 
The tables in this Appendix provide additional information for the reviews (WP1.1, 1.2 and 1.3) 
conducted for diabetes.  
 
Table A1: Quality assessment of Janssen et al. review of EQ-5D in diabetes(2) 
Quality assessment criteria Compliance with criteria 
AMSTAR  
Was an a priori design provided? Yes 
Was there duplicate study selection and data 
extraction? 
Unclear 
Were the methods used to combine the findings of 
the studies appropriate? 
Unclear 
Was the scientific quality of the included studies 
assessed and documented? 
Unclear 
Was the scientific quality of the included studies used 
appropriately in formulating conclusions? 
Unclear 
Overall judgement of quality of review Mostly unclear quality 
Quality of the searches  Acceptable 
Strength of the evidence  
Were the conclusions robust and conclusive? No, evidence was mixed and limited 
Quantity of the evidence  
Was there enough data to be confident that any 
additional data published subsequently would be very 
unlikely to change the conclusions drawn? 
yes 
Adequacy of data reported  
Did the review provide sufficient data to allow 
integration of an update/assessment of the methods 
used? 
No 
Did the review assess EQ-5D in a way compatible with 
the aims of work package 1.1? 
No, wider inclusion criteria, lack of clarity about how 
psychometrics properties assessed 
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Table A2: Characteristics of studies included in the reanalysis of Janssen et al. for diabetes(2) 
Study ref 
Author, 
Year  
Country  Disease/treatment stage Treatment (if any) Study type 
(e.g. cross 
sectional, 
RCT, 
cohort) 
Study objective 
Bech et al. 
2003(6) 
Multi-national 
Australia, Croatia, the Czech 
Republic, France, 
Greece, Israel, Macedonia, 
Poland, Russia, Slovenia 
and Spain. 
Pharmacotherapy naïve Type 2 Diabetes Repaglinide for 
prandial glucose 
regulation 
Placebo 
controlled 
RCT 
To assess the differential impact of the 
prandial glucose regulating oral 
hypoglycaemic drug, repaglinide, and 
placebo upon perceptions of 
quality of life (QoL) and treatment 
satisfaction in pharmacotherapy-naive 
patients with Type 2 diabetes 
Bharmal 
and 
Thomas 
2006(10) 
USA General population, with subgroup of 
patients with diabetes  
NR Cross 
section 
The purpose of this analysis was to 
compare the EQ-5D and the SF-6D 
derived from the SF-12 to examine any 
ceiling effects in the EQ-5D and the SF- 6D 
descriptive systems in the US general 
population. 
Clarke 
et al. 
2002(20) 
UK Type 2 diabetes NR Cross 
section 
The aim of this study was to analyze 
quality-of-life data from the United 
Kingdom Prospective Diabetes Study 
(UKPDS) to estimate the impact of 
diabetes-related complications on utility-
based measures of quality of life. 
Currie et 
al. 
2007(11) 
UK Type 1 or type 2 diabetes NR Cross 
section 
The aim of this study was to characterize 
accurately DPN symptom severity in 
people with diabetes and correlate this 
with healthcare resource use, thus 
financial costs, in the UK. 
Glasziou 
et al. 
2007(17) 
Australia Normotensive patients with type 2 
diabetes 
Various treatment 
regimens  
Cross 
section 
(using 
patients in 
The purpose of this study is to compare 
summary statistics of the estimated utility 
values produced by different algorithms 
for common complications of diabetes. In 
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Study ref 
Author, 
Year  
Country  Disease/treatment stage Treatment (if any) Study type 
(e.g. cross 
sectional, 
RCT, 
cohort) 
Study objective 
current 
RCT) 
particular we are interested to see if 
there are systematic differences in both 
the absolute mean utility values and the 
deviations associated with each type of 
diabetes-related complication. 
Gore et al. 
2005(12) 
USA Patients with physician-diagnosed 
diabetic distal symmetrical 
sensorimotor polyneuropathy with 
painful symptoms (burning, prickling, 
tingling, and/or shooting pain in toes, 
feet, legs, and/or hands) of at least 
ƚŚƌĞĞŵŽŶƚŚƐ ?ĚƵƌĂƚŝŽŶ ? 
NR Cross 
section 
The aim was to evaluate pain severity, 
pain-related interference with function, 
sleep impairment, symptom levels of 
anxiety and depression, and quality of life 
among patients with PDPN. 
Hoffman 
et al. 
2008(13) 
 
 
19 countries across 3 regions 
of the world: Asia (Indonesia, 
Malaysia, Philippines, Republic 
of Korea, Singapore, Taiwan, 
and Thailand), Latin America 
(Argentina, Brazil, Chile, 
Colombia, Ecuador, Mexico, 
and Venezuela) and the Middle 
East (Jordan, Lebanon, Saudi 
Arabia, Turkey, and United 
Arab Emirates). 
Type 1 or 2 diabetes with painful 
symmetrical sensorimotor DPN for >12 
months, <5 years, and a pain score of at 
least 40 mm on the 100 mm visual 
analog scale (VAS) of the Short Form 
McGill Pain Questionnaire both at 
screening and randomization, and a 
score of at least 4 on a 0 to 10 numerical 
rating scale of average pain in the week 
prior to baseline. 
NR Post hoc 
analysis of 
RCT 
To understand the human impact of 
painful DPN on patients in Asia, Latin 
America, and the Middle East, we 
analyzed baseline data taken from 
patients in a clinical study prior to 
receiving treatment. 
Johnson 
et al. 
2000b(19) 
USA Random selection of general population NA Time series 
(Annually, 
over 3 
years) 
To compare the health related quality of 
life of people with diabetes to those 
without chronic conditions 
Lloyd et al. 
2008(9) 
UK Patients with diabetic retinopathy 
 
Patients with type 1 or 2 diabetes, but 
no retinopathy 
NR Cross 
section 
The study was designed to elicit 
preferences regarding different severities 
of retinopathy from people with DR, 
people with diabetes with no retinopathy 
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Study ref 
Author, 
Year  
Country  Disease/treatment stage Treatment (if any) Study type 
(e.g. cross 
sectional, 
RCT, 
cohort) 
Study objective 
 
Members of the UK general population 
but who face the prospect of DR in the 
future, and a group of members of the 
general public. In addition, patient groups 
completed two generic HRQL measures 
and a vision-specific measure [National 
Eye Institute Visual Functioning 
Questionnaire (NEI-VFQ-25)] to also 
document the burden of DR. 
Matza et 
al. 
2007a(24) 
UK Type 2 diabetes Diet/exercise: 
10.8% 
Oral meds: 65.4% 
IV meds ± other 
treatment: 23.8% 
Cross 
section 
To validate two generic measures in 
patients with T2DM. 
Redekop 
et al. 
2002(7) 
Netherlands Type 2 diabetes Approx. 67% oral 
treatment 
Others used 
diet/exercise or 
insulin 
Cross 
section 
To estimate the health-related quality of 
life (HRQOL) and treatment satisfaction 
for patients with type 2 diabetes in the 
Netherlands and to examine which 
patient characteristics are associated with 
quality of life and treatment satisfaction. 
Sakthong 
et al 
2008(22) 
Thailand Type 2 diabetes ŽƵƚƉĂƚŝĞŶƚƐ ?ĂŐĞĚA䠀  ? ?
years 
NR Cross 
section 
to examine the differences and 
agreements between these three 
weights, psychometric properties 
including test-retest reliability, 
convergent and known-groups validity, 
and the impact of differences in the EQ-
5D scores on the outcome of cost-utility 
analysis in Thai people. 
Tolle et al. 
2006(16) 
France, Germany, Italy, 
Netherlands, Spain, United 
Kingdom 
Patients with painful DPN Various, including 
antidepressants, 
sedatives, 
analgesics, 
Cross 
section 
To determine the patient burden of 
painful diabetic peripheral neuropathy 
(DPN) with respect to pain intensity and 
impact on patient functioning and to 
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Study ref 
Author, 
Year  
Country  Disease/treatment stage Treatment (if any) Study type 
(e.g. cross 
sectional, 
RCT, 
cohort) 
Study objective 
antiepileptics. characterize relevant DPN treatment 
patterns. 
Vernon 
et al. 
2008(14) 
 
 
Unclear, 4 different RCTs Diagnosis of Type 1 or 2 diabetes 
mellitus; diagnosis of diabetic, distal, 
symmetrical, sensorimotor 
polyneuropathy for one to five years 
ǁŝƚŚŚĞŵŽŐůŽďŝŶ ?ĐůĞǀĞůƐŽĨA䜃? ?A? ?
and at the baseline and randomization 
ǀŝƐŝƚƐ ?ĂƐĐŽƌĞŽĨA? ? ?ŵŵŽŶƚŚĞsŝƐƵĂů
Analog Scale (VAS) of the Short-Form 
McGill Pain Questionnaire (SF-MPQ). 
NR Post hoc 
analysis of 8 
RCTs 
To evaluate the psychometric 
characteristics of the Daily Sleep 
Interference Scale (DSIS) in patients with 
painful diabetic peripheral neuropathy 
(DPN) or postherpetic neuralgia. 
Vexiau 
et al. 
2008(15) 
France dǇƉĞ ?ĚŝĂďĞƚĞƐ ?ǁŚŽǁĞƌĞA? ? ?ǇĞĂƌƐ
old and who had been treated with 
metformin and a sulphonylurea for at 
least 6 months 
Treated with 
metformin and a 
sulphonylurea 
Cross 
section 
To examine patient-reported experience 
of hypoglycaemia, worry about 
hypoglycaemic symptoms and the impact 
ŽĨŚǇƉŽŐůǇĐĂĞŵŝĂŽŶƉĂƚŝĞŶƚƐ ?ƋƵĂůŝƚǇŽĨ
life associated with use of sulphonylurea 
co-administered with metformin. 
Wee et al. 
2006(21) 
Singapore English-speaking with type 1 or type 2 
ĚŝĂďĞƚĞƐ ?ĂŐĞĚA䠀  ? ?ǇĞĂƌƐ 
NR Cross 
section 
To evaluate and validate the ADDQoL 
questionnaire in English-speaking 
patients with diabetes in Singapore 
PDPN, painful diabetic peripheral neuropathy; DPN, diabetic peripheral neuropathy; IV, intravenous; RCT, randomised controlled trial; UKPDS, United Kingdom Prospective 
Diabetes Study; PDPN, painful diabetic peripheral neuropathy; VAS, visual analogue scale; ADDQoL, audit of diabetes-dependent quality of life 
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Table A3: Patient characteristics of studies included in the reanalysis of Janssen et al. for diabetes[Janssen et al. 2011] 
Study ref 
Author, Year 
Number of 
participants 
recruited 
Age in years 
mean (sd); range 
Male %  Ethnicity % Other characteristics % Missing data (patients completing 
study) include reasons for non-
completion if given 
Bech et al. 
2003(6) 
253 
Repaglinide: 164 
Placebo: 89 
Repaglinide: 56.9 
(8.6); 40 to 81 
 
Placebo: 57.3 
(8.2); 40 to 76 
57 Rapaglinide, Placebo 
African: 0.6, 0 
Caucasian: 98.2, 98.9 
Asian: 0, 0 
Other: 1.2, 1.1 
Duration of diabetes  
mean (SD) years 
Rapaglinide: 2.77 (4.2) 
Placebo: 2.81 (4.96) 
Withdrawals 
Rapaglinide: 17.1% 
Placebo: 29.2% 
Bharmal and 
Thomas 
2006(10) 
Diabetes: 165  Mean NR 53 White: 85 
African American: 10 
Asian or Pacific Islander: 
4 
Native American or 
Eskimo: 9 
NR NA (only included respondents 
with the full set of variables 
required) 
Clarke et al. 
2002(20) 
124 in this analysis 62.3 NR NR NR NR 
Currie et al. 
2007(11) 
1,298 64 (NR) 56 NR Complication: type 1; type 
2 
 
Acute MI: 5.5; 5.4 
Stroke: 5.1; 4.2 
Amputation: 2.1; 0.7 
PVD no amputation: 5.1; 
3.6 
PVD with amputation: 1.3; 
0.7 
Suffer/ed leg ulcer: 13.6; 
9.8 
ESRD: 11.4; 6.2 
Retinopathy: 22.9; 14.6 
Severe loss of vision: 1.3; 
0.1 
NA 
Glasziou et al. 
2007(17) 
978 67 (range 55 to 
89) 
71 NR NR NR 
Gore et al. 265 61.3 (12.8) 45 African American/Black: Type of diabetes 0 patients 
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Study ref 
Author, Year 
Number of 
participants 
recruited 
Age in years 
mean (sd); range 
Male %  Ethnicity % Other characteristics % Missing data (patients completing 
study) include reasons for non-
completion if given 
2005(12) 18.8 
Asian: 2.4 
Caucasian: 53.3 
Hispanic/Latino: 9.8 
Native American: 0.4 
Pacific Islander: 0 
Other: 0.4 
Multi-racial: 3.1 
Missing: 11.8 
Type I: 12.5 
Type II: 86.3 
Missing: 1.2 
Hoffman et al. 
2008(13)  
401 57 (10) 39 White: 29.7 
Black: 3 
Asian: 51.6 
Other: 15.7 
NR NR 
Johnson et al. 
2000b(19) 
Diabetics, n=85 
No chronic 
condition, n=463 
Diabetics: 69 
(10.9) 
No chronic 
condition: 48.1 
(12.7) 
Diabetics: 78.4 
No chronic 
condition: 
75.1 
NR NR NR 
Lloyd et al. 
2008(9) 
DR, Diabetes no 
DR, general public:  
122, 49, 150 
 
DR; Diabetic no 
DR; general public:  
62.2 (12.6); 52.6 
(15.2); 44.4 (15.9) 
50 Ethnicity: DR; Diabetic 
no DR; general public 
 
White: 79; 44; 72 
Asian/ Asian British: 11; 
25; 8 
Black/Black British: 8; 
23; 10 
Chinese/other: 0; 0; 4 
NR NR 
Matza et al. 
2007a(24) 
132 recruited 
130 analysed 
55.7 (10.3) 65 White: 80.8 
Black: 6.2 
Indian: 6.2 
Other 6.9 
Hypertension: 36.9 
Diabetic retinopathy: 5.4 
Depression/other mental 
health condition: 13.1 
Other health condition: 
43.1 
2 unable to complete full set of 
questionnaires  W reason not 
reported. 
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Study ref 
Author, Year 
Number of 
participants 
recruited 
Age in years 
mean (sd); range 
Male %  Ethnicity % Other characteristics % Missing data (patients completing 
study) include reasons for non-
completion if given 
None: 34.6 
Redekop et al. 
2002(7) 
1,371 64.9 49.8 NR Complications 
microvascular: 22  
macrovascular: 15  
micro- and 
macrovascular: 16  
Missing data for EQ-5D: 16% 
Sakthong et al 
2008(22) 
303 61.6 (11.4) 29 NR Neuropathy: 40.9 
Retinopathy: 16.8 
Nephropathy: 8.3 
Cardiovascular disorders: 
14.5 
NR 
Tolle et al. 
2006(16) 
140 65.6 (11.2) 58.3 NR NR NR 
Vernon et al. 
2008(14) 
 
 
1,124 59 58 White: 92 
Black: 4 
Hispanic: 3 
Asian: <1 
American 
Indian/Alaskan: <1 
Type 1: 11.6 
Type 2: 88.4 
NR 
Vexiau et al. 
2008(15) 
400 62.1 (10.7) 53.6 NR Complications 
Macrovascular:: 19.9 
Microvascular: 8.3 
Major medical events: 8.3 
NR 
Wee et al. 
2006(21) 
136 analysed  52 55.3 Chinese: 49 
Indian: 33.8 
Malay: 12.6 
NR Of 173 respondents, 37 excluded: 
3 did not complete ADDQoL 
6 completed by a caregiver  
12 missed >6 items on ADDQoL 
2 missed items on EQ-5D 
12 skipped EQ-VAS 
2 missed EQ-VAS and items on EQ-
5D 
NA, not applicable; NR, not reported; MI, myocardial infarction; ESRD, end-stage renal disease; SD, standard deviation; MI, myocardial infarction; PVD, peripheral vascular 
disease; DR, diabetic retinopathy; ADDQoL, audit of diabetes-dependent quality of life; EQ-VAS, EuroQol visual analogue scale 
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Table A4: Characteristics of psychometric analyses of studies included in the reanalysis of Janssen et al. for diabetes (2) 
 GENERIC MEASURES OTHER MEASURES USED  
Study ref 
Author, Year 
Descriptive 
system  
Tariff used  Mean (SD); 95% CI Condition-specific 
HRQL measures  
Clinical measures  Qualitative 
questions  
Other 
generic 
Bech et al. 
2003(6) 
EQ-5D UK (Dolan) Baseline 
Rapaglinide: 0.82 
Placebo: 0.83 
WHO-DTSQ 
 
HbA1c None WHO-WBQ 
Bharmal and 
Thomas 2006(10) 
EQ-5D USA (Shaw 
2005) 
1 (recruited those in 
full health) 
None None None SF-6D 
Clarke et al. 
2002(20) 
EQ-5D UK NR NA NA NA NA 
Currie et al. 
2007(11) 
EQ-5D Unclear Type1: median 0.656 
(IQR 0.248  W 0.848) 
Type 2: median 0.691 
(IQR 0.516  W 0.796) 
NTSS-6 
 
None None None for 
analysis 
Glasziou et al. 
2007(17) 
EQ-5D UK 0.801 (0.206) None Serious adverse events None None 
Gore et al. 
2005(12) 
EQ-5D Unclear 0.5 (0.3) BPI-DPN None None None for 
analysis 
Hoffman et al. 
2008(13)  
EQ-5D UK 0.44 (0.34)  mBPI-sf None None None for 
analysis 
Johnson et al. 
2000b(19) 
EQ-5D UK Diabetics 0.72; 0.69 to 
0.75 
No chronic condition: 
0.96 (0.94 to 0.97) 
None None None None  
Lloyd et al. 
2008(9) 
EQ-5D Unclear NR  NEI-VFQ-25 VA  HUI-3 
Matza et al. 
2007a(24) 
EQ-5D UK (Dolan) 
Krabbe 2003  
0.75 (0.3) ADS 
DSC-R 
None None PGWB 
Redekop et al. 
2002(7) 
EQ-5D UK (Dolan) 0.74 (0.27) WHO-DTSQ 
 
None None None 
Sakthong et al. 
2008(22) 
EQ-5D UK (Dolan) 0.76 (95% CI 0.74 W0.78) CES-D HbA1c 
BMI 
Neuropathy 
Retinopathy 
None None 
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 GENERIC MEASURES OTHER MEASURES USED  
Study ref 
Author, Year 
Descriptive 
system  
Tariff used  Mean (SD); 95% CI Condition-specific 
HRQL measures  
Clinical measures  Qualitative 
questions  
Other 
generic 
Nephropathy 
Cardiovascular disorders 
Tolle et al. 
2006(16) 
EQ-5D UK NR mBPI-SF None None None  
Vernon et al. 
2008(14) 
EQ-5D None NR Sleep Interference 
Score 
None None None for 
analysis 
Vexiau et al. 
2008(15) 
EQ-5D UK 0.77 (0.24) score 
0.79 (0.22) weighted 
score 
 
 
Hypoglycaemia symptoms 
(any, mild, moderate, severe) 
none none 
Wee et al. 
2006(21) 
EQ-5D UK 0.812 (range:  W0.008 W
1) (n=148) 
ADDQoL None none none 
WHO-DTSQ, WHO Diabetes treatment satisfaction questionnaire; WHO-WBQ, WHO wellbeing questionnaire; HbA1c, glycated haemoglobin; PGWB, psychological general 
wellbeing index; ADS, appraisal of diabetes scale; DSC-R, diabetes symptom checklist-revised; NEI-VFQ-25, National Eye Institute Visual Functioning Questionnaire; VA, 
visual acuity; NTSS-6, Neuropathy Total Symptom Score-6 questionnaire; QOL-DN, Quality of Life Questionnaire WDiabetic Neuropathy; BPI-DPN, brief pain inventory 
modified for pain in diabetic peripheral neuropathy; mBPI-sf, modified brief pain inventory short form; NA, not applicable; ADDQoL, audit of diabetes-dependent quality of 
life; CES-D, Centre for epidemiologic studies  W Depression. 
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Table A5: Know group validity data for studies included in the reanalysis of Janssen et al. for diabetes (2) 
Author, Year Method of measuring validity, Type of 
validity, how (e.g. known group/convergent)? 
Validity results, Group A(n) vs. 
Group B(n)
, 
Mean EQ-5D; mean 
difference in EQ-5D 
ƵƚŚŽƌƐ ?ĐŽŶĐůƵƐŝŽŶƐ ?ŶŽƚĞƐ Our additional conclusions/notes 
Matza et al. 
2007a(24) 
Known group, t-test Comparison group (n): Mean EQ-5D, 
t value 
ADS Median Split  
^^ĐŽƌĞA䜀  ? ? ?ŶA? ? ? ? P ? ? ? ? ? ? ? ? ? ? ? 
ADS Score > 16 (n = 72): 0.65 
 
DSC-R Median Split  
DSC-ZdŽƚĂů^ĐŽƌĞA䜀  ? ? ? ?ŶA? ? ? ? P
0.91, 6.6***  
DSC-R Total Score > 0.7 (n = 69): 
0.61 
 
Preference for Weight Change  
Lose weight (n = 113):0.73, -4.4***  
Stay same (n = 16): 0.92  
 
Experienced Hypoglycemia during 
the day 
Yes (n = 53): 0.68, -2.6*  
No (n = 74): 0.82  
Experienced Hypoglycemia During 
the Night 
Yes (n = 23): 0.60, -3.2** 
No (n = 101): 0.80  
Experienced Hyperglycemia 
Yes (n = 64): 0.73, -1.1  
No (n = 63): 0.78  
 
Type of Treatment  
Injectable (n = 31): 0.65, -1.8  
Oral only (n = 85): 0.78 
The current study provides 
initial data suggesting that 
the EQ-5D and PGWB are 
appropriate for use in 
patients with type 2 
diabetes, and future 
research may provide 
additional support for this 
conclusion. 
This study provides evidence of 
acceptability of EQ-5D (100% 
completion), convergent validity 
(moderate to large correlations 
with majority of ADS and DSC-R 
scales (p<0.001)), known-group 
validity (comparing EQ-5D scores 
for sub-groups categorised by ADS 
score and DSC-R total score 
(p<0.001). However, there was 
some evidence of a ceiling effect 
(self-care: 92% reported no 
problem; preference-based index: 
40% reported full health), and 
potential issues with the 
ophthalmology (relatively small 
correlation EQ-5D preference-
based index and DSC-R 
ophthalmology dimensions, r=0.22 
p<0.05) 
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Author, Year Method of measuring validity, Type of 
validity, how (e.g. known group/convergent)? 
Validity results, Group A(n) vs. 
Group B(n)
, 
Mean EQ-5D; mean 
difference in EQ-5D 
ƵƚŚŽƌƐ ?ĐŽŶĐůƵƐŝŽŶƐ ?ŶŽƚĞƐ Our additional conclusions/notes 
Vexiau et al. 
2008(15) 
Known group, % scoring a problem in each 
group, Chi Squared 
 
Mean EQ-5D in those with and without 
hypoglycaemia, t-test 
 
EQ-5D dimension: % with 
hypoglycaemia who scored 
problem; % without hypoglycaemia 
who scored problem, p value (Chi 
squared) 
 
Mobility problems: 26.7; 20.1, 
p=0.140 
Self-care problems: 9.6; 4.6, p=0.056 
Usual activities problems: 21.3; 14.0, 
p=0.064 
Pain/discomfort problems: 59.6; 
39.5, p=0.0002 
Anxiety/depression problems: 58.1; 
41.1, p=0.0013 
 
EQ-5D summary score: 0.70 (0.26); 
0.80 (0.23), p<0.0005 
 
 All EQ-5D health dimensions 
scores showed differences 
between those with and without 
hypoglycaemia symptoms 
although the differences were 
only statistically significant for 
Pain/discomfort and 
Anxiety/depression (p<0.005).  
 
EQ-5D showed significant 
difference between those with 
and without hypoglycaemia 
symptoms 
Glasziou et al. 
2007(17) 
Known group, interpretation of confidence 
intervals on graph 
Graph presented. EQ-5D mean 
deficit at baseline significant for 
those with: 
 
Stroke and/or TIA 
Peripheral revascularization and/or 
amputation 
MI 
Hospital admin for unstable angina 
Currently treated hypertension 
 
Not significant for: 
Diabetic eye disease including 
blindness in either eye 
 This study provides evidence that 
the EQ-5D can detect differences 
in utility values for diabetic 
complications (Spearman rank 
between EQ-5D and SF6D: 0.837 
for vSF12; 0.842 for vSF36), and 
shows a differences in changes in 
utilities over time when 
comparing patients who do not 
have a serious adverse event and 
those who do. 
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Author, Year Method of measuring validity, Type of 
validity, how (e.g. known group/convergent)? 
Validity results, Group A(n) vs. 
Group B(n)
, 
Mean EQ-5D; mean 
difference in EQ-5D 
ƵƚŚŽƌƐ ?ĐŽŶĐůƵƐŝŽŶƐ ?ŶŽƚĞƐ Our additional conclusions/notes 
Coronary artery bypass graft  
 
Similar graphs shows the same 
pattern of significance for the SF-6D 
(12), whilst the SF-6D (36) fails to 
find a significant difference for MI in 
addition to diabetic eye disease and 
coronary artery bypass graft.  
Sakthong et 
al. 2008(22) 
Known group, z statistic, Mann-Whitney U 
tests. 
Comparison: mean vs. mean; 
difference; z statistic 
HBA1c<7% vs.>7%: 0.79 vs. 0.75; 
0.04; -1.91 
With vs. without neuropathy: 0.81 
vs. 0.69; 0.12**; -5.94 
With vs. without retinopathy: 0.78 
vs.0.69; 0.09*; -2.16 
With vs. without nephropathy: 0.77 
vs. 0.67; 0.10*; -2.57 
With vs. without cardiovascular 
disorder: 0.78 vs. 0.65; 0.13**; -3.48 
 Significant difference seen for 
neuropathy, retinopathy, 
nephropathy and cardiovascular 
disorder, but not for HBA1c. 
Lloyd et al. 
2008(9) 
Known group, no formal comparison statistics, 
compared trend mean scores for decreasing 
level of visual acuity 
Levels of visual acuity range (N): EQ-
5D single index; HUI-3; VFQ-25 total 
score 
 
Diabetic no retinopathy (49): 0.83 ± 
0.20; 0.81 ± 0.20; 90.6 ± 13.1 
6/6 W6/9 VA (68): 0.75 ± 0.23; 0.78 ± 
0.22; 86.3 ± 13.6 
6/12 W6/18 VA (13): 0.50 ± 0.30; 0.30 
± 0.38; 61.5 ± 25.4 
6/24 W6/36 VA (10): 0.68 ± 0.29; 0.61 
± 0.35; 61.1 ± 22.6 
6/60 W6/120 VA (7): 0.53 ± 0.47; 0.52 
No conclusion about 
psychometrics drawn. 
The analyses show the EQ-5D is 
able to detect a difference in 
mean utility for sub-groups with 
different levels of impairment as 
defined by levels of visual acuity.  
The trend follows those observed 
in the HUI-3 and the VFQ-25 total 
score. 
Although the differences are not 
significant (p-value not reported), 
this is possibly due to the small 
sample sizes.     
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Author, Year Method of measuring validity, Type of 
validity, how (e.g. known group/convergent)? 
Validity results, Group A(n) vs. 
Group B(n)
, 
Mean EQ-5D; mean 
difference in EQ-5D 
ƵƚŚŽƌƐ ?ĐŽŶĐůƵƐŝŽŶƐ ?ŶŽƚĞƐ Our additional conclusions/notes 
± 0.50; 39.5 ± 24.3 
Counting fingers Whand motion (3): 
0.34 ± 0.36; 0.37 ± 0.00; 29.2 ± 16.1 
 
No formal comparison statistics, but 
can observe that the mean EQ-5D 
scores decrease as the visual acuity 
(VA) gets worse. Very worse VA has 
much lower EQ than least worse VA 
, which is as expected. But the EQ-
5D values in the middle VA 
subgroups do not follow same 
trend. This anomaly is observed in 
the HUI3 and the VFQ-25 data and is 
likely due to the very small sample 
sizes in the sub-groups (N: 3-49)  
Currie et al. 
2007(11) 
Known group, comparison of mean scores for 
severity by NTSS-6 scale,  Kruskal-Wallis H test 
NTSS-6 score category (n): EQ-5D 
mean score; SF-36 mean score; QOL-
DN mean score 
 
0 (335): 0.81;59.92; 25.84 
AN ?A? ? ? ? ? ? ? ? ? ? P ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? 
AN ? ? ? ?A? ? ? ? ? ? ? ? ? ? P ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? 
>7.64 (202): 0.25; 25.54; 48.06 
 
Kruskal W allis H-test, p<0.001 for 
EQ-5D and QOL-DN 
ANOVA, p<0.001 for SF-36 
No conclusion about 
psychometrics drawn. 
EQ-5D was able to detect 
significant differences in utilities 
across sub-groups categorised by 
NTSS-6-SA score, and show a 
similar trend in mean scores 
observed in the SF36 global 
scores, including a larger 
difference between groups at the 
extremes of the sub-groups. 
Gore et al. 
2005(12) 
Known group, mean EQ-5D score by pain 
category 
BPI-DPN pain category: EQ-5D mean 
score (sd) 
 
Mild: 0.7 (0.2) 
Moderate: 0.5 (0.3) 
 EQ-5D was able to detect 
significant differences in mean 
utilities for sub-groups categorised 
by BPI-DPN score (p<0.01). 
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Author, Year Method of measuring validity, Type of 
validity, how (e.g. known group/convergent)? 
Validity results, Group A(n) vs. 
Group B(n)
, 
Mean EQ-5D; mean 
difference in EQ-5D 
ƵƚŚŽƌƐ ?ĐŽŶĐůƵƐŝŽŶƐ ?ŶŽƚĞƐ Our additional conclusions/notes 
Severe: 0.2 (0.3) 
 
ANOVA f 44.7734, p< 0.00001 
Hoffman 
et al. 
2008(13)  
Known group, EQ-5D mean score by pain 
category, pairwise comparison 
mBPI-sf pain category: EQ-5D mean 
score (SD)  
 
Asia  ANOVA f value 28.1, p<0.0001  
Mild:0.68 (0.06) 
Moderate: 0.61 (0.24) 
Severe: 0.27 (0.36) 
 
Latin America ANOVA f value 8.8, 
p<0.0003  
Mild: 0.40 (0.31) 
Moderate: 0.54 (0.28) 
Severe: 0.28 (0.34) 
 
Middle east ANOVA f value 4.1, 
p<0.019 
Mild: 0.67 (0.09) 
Moderate: 0.50 (0.31) 
Severe: 0.36 (0.36) 
 When sub-grouping by mBPI-sf 
Average Pain severity, EQ-5D (UK 
tarrif) was able to detect a 
statistically sig difference (p<0.05) 
in 3 different populations  
Tolle et al. 
2006(16) 
Known group, EQ-5D scores according to Pain 
Severity Index Categories, ANOVA 
EQ-5D scores according to Pain 
Severity Index Categories (mBPI-sf 
scores): 
 
Mild (1-3): 0.59 
Moderate (4-6): 0.43 
Severe (7-10): 0.20, P <0.001 
 EQ-5D mean scores decrease for 
subgroups categorised by Pain 
severity index (mild, moderate, 
severe) and the data seem to 
suggest a negative correlation 
between the EQ-5D and the Pain 
Interference data, as would be 
expected. 
*p < 0.05; **p < 0.01; ***p < 0.001 
ANOVA, analysis of variance; ADS, appraisal of diabetes scale; DSC-r, diabetes symptom checklist  W revised; VFQ-25, visual functioning questionnaire; HUI-3, Health utilities 
index -3; NTSS-6, Neuropathy Total Symptom Score-6 questionnaire; QOL-DN, Norfolk Quality of Life Questionnaire-Diabetic Neuropathy; BPI-DPN, brief pain inventory 
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Author, Year Method of measuring validity, Type of 
validity, how (e.g. known group/convergent)? 
Validity results, Group A(n) vs. 
Group B(n)
, 
Mean EQ-5D; mean 
difference in EQ-5D 
ƵƚŚŽƌƐ ?ĐŽŶĐůƵƐŝŽŶƐ ?ŶŽƚĞƐ Our additional conclusions/notes 
modified for pain in diabetic peripheral neuropathy; mBPI-sf, modified brief pain inventory short form 
 
Table A6: Convergent validity data for studies included in the reanalysis of Janssen et al. for diabetes (2) 
Author, 
Year 
Method of measuring validity, Type of validity, 
how (e.g. known group/convergent)? 
Validity results, Group A(n) vs. Group B(n)
, 
Mean EQ-5D; 
mean difference in EQ-5D 
ƵƚŚŽƌƐ ?
conclusions/notes 
Our additional 
conclusions/notes 
Bech et al. 
2003(6) 
Convergent, correlation between EQ-5D and 
HbA1c , test unclear 
There were no significant correlations between change in 
EQ-5D and change in HbA1c. 
  
Redekop 
et al. 
2002(7) 
Convergent, correlation between EQ-5D and 
WHO-DTSQ, Pearson correlation 
Correlation between WHO-DTSQ and EQ-5D  
Pearson r=0.28 p<0.0001 
 EQ-5D does not 
have a question 
directly relating to 
treatment 
satisfaction and 
thus EQ-5D unlikely 
to detect a change, 
unless the 
satisfaction has an 
indirect impact on 
HRQoL 
Matza et 
al. 
2007a(24) 
Convergent validity, correlation between EQ-5D 
score and DSC-R subscales, Spearman 
correlation 
ADS: -0.52*** 
Total Score DSC-R: -0.64*** 
Fatigue: -0.61*** 
Cognitive: -0.46*** 
Pain: -0.51*** 
Sensory: -0.53*** 
Cardiology: -0.56*** 
Ophthalmology: -0.22* 
Hypoglycemia: -0.44*** 
Hyperglycemia: -0.46*** 
BMI: -0.27** 
Correlations between 
the EQ-5D index and 
the DSC-R subscales 
ranged from -0.44 to -
0.61 (all p < 0.001), 
except for the 
ophthalmology 
subscale (r= -0.22, 
p<0.05)  
 
Vernon 
et al. 
2008(14) 
Convergent, correlation between EQ-5D and 
DSIS, spearman correlation coefficients. 
Correlation with Daily Sleep Interference Score at 
baseline; 12 weeks 
 
Small to moderate 
correlations 
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Author, 
Year 
Method of measuring validity, Type of validity, 
how (e.g. known group/convergent)? 
Validity results, Group A(n) vs. Group B(n)
, 
Mean EQ-5D; 
mean difference in EQ-5D 
ƵƚŚŽƌƐ ?
conclusions/notes 
Our additional 
conclusions/notes 
Mobility: 0.14; 0.19 
Self care: 0.13; 0.08 
Usual activities: 0.23; 0.25 
Pain/discomfort: 0.35; 0.44 
Anxiety/depression: 0.26; 0.24 
Glasziou 
et al. 
2007(17) 
Convergent validity, EQ-5D to SF- ? ?^ƉĞĂƌŵĂŶ ?Ɛ
rank 
Correlations between utility measures on ranking of 
severity of seven complications of diabetes: 
 
EQ-5D to SF-6D (SF12): 0.837 
EQ-5D to SF-6D (SF36): 0.842 
 There was a strong 
correlation between 
the EQ-5D and both 
the SF6D  
Wee et al. 
2006(21) 
Convergent validity, EQ-5D to ADDQoL, 
^ƉĞĂƌŵĂŶ ?ƐƌĂŶŬ 
Correlation between scores for those scoring better  QoL 
on ADDQoL and EQ-5D score, spearman rank correlation 
= 0.54 
 The EQ-5D 
correlates with the 
ADDQoL 
Sakthong 
et al. 
2008(22) 
Convergent validity, EQ-5D to other measures, 
^ƉĞĂƌŵĂŶ ?ƐƌĂŶŬ 
^ƉĞĂƌŵĂŶ ?Ɛrho correlation coefficients, p value 
Duration of diabetes: -0.14, p<0.01 
BMI: -0.15, p<0.01 
HBA1c: -0.17, p<0.01 
Number of diabetic complications: -0.40, p<0.01 
CES-D score: -0.49, p<0.01 
ĂƐĞĚŽŶŽůƚŽŶ ?Ɛ 
[colton 1974] criteria, 
EQ-5D had small to 
medium correlations 
with duration of 
diabetes, BMI, HBA1c, 
number of 
complications and 
CES-D. 
 
WHO-DTSQ, WHO Diabetes treatment satisfaction questionnaire; HbA1c, glycated haemoglobin; ADS, appraisal of diabetes scale; DSC-R, Diabetes symptom checklist  W 
revised; BMI, body mass index; ADDQoL, audit of diabetes-dependent quality of life; CES-D, Centre for epidemiologic studies  W Depression; DSIS, daily sleep interference 
score 
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Table A7: Reliability data for studies included in the reanalysis of Janssen et al. for diabetes (2) 
Author, 
Year 
Method of measuring validity, Type of validity, 
how (e.g. known group/convergent)? 
Validity results, Group A(n) vs. Group B(n)
, 
Mean EQ-5D; 
mean difference in EQ-5D 
ƵƚŚŽƌƐ ?
conclusions/notes 
Our additional 
conclusions/notes 
Clarke 
et al. 
2002(20) 
Test-retest reliability, 4 month interval, ICC For the 5 dimensions of the EQ- ? ?ƚŚĞʃƐƚĂƚŝƐƚŝĐƐƌĂŶŐĞĚ
from 0.59 (95% confidence interval [CI] = 0.45 W0.74) for 
the mobility dimension to 0.26 (95% CI = 0.11 W0.40) for 
the pain dimension. The ICC was 0.59 (95% CI = 0.41 W
0.72) for the tariff scores, and therefore fell into the 
ĐĂƚĞŐŽƌǇŽĨ “ŐŽŽĚ ? ? 
ZĞůŝĂďŝůŝƚǇǁĂƐ “ŐŽŽĚ ? ?  
Sakthong 
et al. 
2008(22) 
Test-retest reliability, one week interval, ICC Tested at one and two weeks. ICC = 0.74 (95% CI 0.57 to 
0.84), p<0.001 
 
 According to Rosner 
2000,[Rosner 200] 
agreement is good. 
N, number; ICC, intraclass correlation coefficient 
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Table A8: Responsiveness data for studies included in the reanalysis of Janssen et al. for diabetes [Janssen et al 2011] 
Author, 
Year 
Method of measuring validity Validity results ƵƚŚŽƌƐ ?
conclusions/notes 
Our additional 
conclusions/notes 
Bech et al. 
2003(6) 
Responsiveness, change over time EQ-5D detected no change over time in response to 
treatment, where the WHO-DTSQ did. WHO-WBQ also 
detected no change. 
 
 
Ceiling effect in EQ-5D 
 “ŐĞŶĞƌŝĐƵƚŝůŝƚǇŝŶĚĞǆ
like the EQ-SD may be 
too insensitive to be 
used in the setting of 
patients with baseline 
wellbeing scores close 
to the normal 
ƉŽƉƵůĂƚŝŽŶ ? ?
 
Johnson 
et al. 
2000b(19) 
Responsiveness, change over time, ANCOVA Within subject effects analysis for time and diabetes 
status:  f 4.49 (p=0.012) 
 
Year: diabetic mean (95% CI); no chronic condition mean 
(95% CI) 
1997: 0.72 (0.69 to 0.75); 0.96 (0.94 to 0.97) 
1998: 0.68 (0.65 to 0.61); 0.96 (0.94 to 0.98) 
1999: 0.65 (0.69 to 0.75);0.94 (0.93 to 0.96) 
 
When adjusted for age: f 3.14 (p=0.044) 
Significantly greater 
decrease in HRQoL 
among people with 
diabetes compared to 
those without 
diabetes with no 
chronic conditions. 
 
Matza et 
al. 
2007a(24) 
Floor/Ceiling effect Measure: % at floor, % at ceiling 
 
EQ-5D: 0%, 40% 
PGWB: 0%, 0% 
Although all 
participants in the 
current sample had 
type 2 diabetes, 40% 
of the participants had 
the maximum EQ-5D 
index score of 1 which 
theoretically 
represents perfect 
health status. This 
ceiling effect suggests 
that the brief EQ-5D 
may not reflect the 
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Author, 
Year 
Method of measuring validity Validity results ƵƚŚŽƌƐ ?
conclusions/notes 
Our additional 
conclusions/notes 
health-related 
problems of all 
patients with type 2 
diabetes, particularly 
patients whose 
symptoms have an 
impact on functional 
domains other than 
the five EQ-5D 
dimensions. 
Bharmal 
and 
Thomas 
2006(10) 
Ceiling effect For the 165 patients with DM who reported no 
impairment on EQ-5D index (EQ-5D=1): 
Mean (SE) 
PCS-12: 52.28 (0.42), P<0.001 compared to those with no 
medical conditions 
MCS-12: 55.59 (0.42), NS 
SF-6D: 0.885 (0.0073), NS 
Ceiling effect of EQ-5D  
Wee et al. 
2006(21) 
Ceiling effect 37.8% respondents did not report any problems on the 
EQ-5D 
Those who reported full health on the EQ-5D had a mean 
ADDQoL of -3.4 (SD 2.49) 
 
  
WHO-DTSQ, WHO Diabetes treatment satisfaction questionnaire; WHO-WBQ, WHO wellbeing questionnaire; ANCOVA, analysis of covariance; PGWB, Psychological General 
Well-Being Index; 95% CI, 95% confidence interval; DM, diabetes mellitus; SE, standard error; PCS-12, physical component summary of the SF-12; MCS-12, mental 
component summary of the SF-12; ADDQoL, audit of diabetes-dependent quality of life 
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Table A9: Optional fields collected in the diabetes NCA (WP1.3) 
PATIENT DEMOGRAPHIC/OBSERVATION DATA
a 
 Ethnic category, Death date 
PROVIDER INFORMATION
a 
 No optional fields 
SURGERY
a 
 Provider organisation, ASA grade, Cancer treatment curability, Date of surgery, Surgical urgency mode of 
operation, Consultant, Primary procedure, Surgical access  
CLINICAL HISTORY
a 
  No optional fields 
OBSERVATIONS
a 
  Person observation and dates for: BMI, Systolic blood pressure, Diastolic blood pressure, HbA1c level, 
Serum creatinine level, Urinary albumin level (and testing method), Albuminuria stage 
(normoalbuminuria, microalbuminuria, macroalbuminuria), Total serum cholesterol level, Diabetes 
routine reviews and dates for: Eye examination, Foot examination; Smoking status, Patient education 
review and date, Diabetes structured education programme (DESMOND) offered and date offered, 
Diabetes structured education programme attended and date attended.  
2 CODES 
b 
  Persistent proteinuria, Ischemic heart disease diagnosis and date of diagnosis
* 
PATIENT EXPERIENCE QUESTIONNAIRE (Inpatient Audit 2013, completed by patient) 
Section A. Background Information 
 Since being admitted to hospital, have you been visited by any specialist diabetes staff? 
While in hospital, did a nurse or doctor make a specific effort to examine your bare feet? 
Has anyone asked you about your usual diabetes medications pre-admission? 
Has anyone asked you about how well your diabetes is controlled at present? 
Has anyone asked about which health care professional looks after your diabetes care? 
Did anyone explain that your diabetes treatment may have to change because of your admitting 
condition? 
Were you involved in the planning of your diabetes treatment as much as you would have liked? 
Have hospital staff taken your treatment preferences into account when caring for you? 
Have you been able to take control of your own diabetes care while in hospital to the extent that you 
would like? 
Do you think that the hospital staff caring for you know that you have diabetes? 
Do you take insulin for your diabetes? 
Are you allowed to administer insulin yourself while in hospital? 
Are you able to test your own blood sugar level while in hospital? 
Have you experienced any of the following difficult situations while in hospital (unexpectedly high blood 
sugar (hyper), unexpectedly low blood sugar (hopo), changes to meal times that affect control of your 
diabetes?, None of these) 
Did staff respond appropriately to manage the situation? 
Have you needed food to be brought into hospital in order to meet your dietary requirements and/or to 
manage your diabetes? 
Has the hospital provided the right type of food for you to manage your diabetes 
During this admission, how often was the choice of meal suitable for your diabetes? 
During this admission, how often was the timing of meals suitable for your diabetes? 
Do you feel that the hospital staff who look after you know enough about diabetes to meet your needs 
while in hospital 
If you have had questions about your diabetes, were staff able to answer these in a way you could 
understand? 
While in hospital, have you received enough emotional support from staff to manage your diabetes 
How good do you think the staff are at working together as a team in managing your diabetes 
How satisfied are you with the overall care of your diabetes while you were in hospital? 
If there is anything else you would like to tell us about the diabetes care you have received during this 
hospital stay, please do so in here, e.g. things that could be improved or anything you found particularly 
good or bad about your care 
NATIONAL DIABETES INPATIENT AUDIT 2013 (Bedside Audit Questionnaire, completed by medical staff)
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SECTION A. BACKGROUND INFORMATION
 
 Specialty of Ward, Speciality of consultant, 
Patient age, Patient gender, Patient ethnic background 
Patient diabetes type on admission (eg T1, T2 insulin treated, diet only, pancreatitis, MODY etc) 
Is the patient being treated with sulponylurea, Is the patient having enteral feeding, How long has the 
patient had diabetes, Was the patient cognitively impaired at the time of the audit, Number of nights in 
hospital, type of admission (elective, emergency, transfer), Main reason for admittance (DKA, 
hyperglycaemia with established diabetes, active diabetic foot disease, non-medical etc),   
KNOWN DIABETIC COMPLICATIONS 
 Receiving renal replacement therapy, Foot disease, 
SECTION B. DIABETES CONTROL
 
  Glucose chart available for review, Patient currently on intravenous insulin infusion? Looking at the 
previous 7 days, on how many days has blood glucose monitoring been carried out? On how many of 
these days was the frequency of monitoring appropriate? 
On the days identified, i.e. in the previous 7 days, and counting only blood glucose readings separated by 
a 4 hr period: No. of glucose readings between 3-3.9 (or <3) mmol/L, Was the treatment of 
hypoglycaemia documented. Was the treatment in accordance with local guidelines,  
No. of episodes of hypoglceamia requiring injectable treatment . If there has been hypoglycaemia during 
the last 7 days, please indicate the number of episodes in each of the following time periods etc 
EŽ ?ŐŽŽĚĚŝĂďĞƚĞƐĚĂǇƐ ?ŝŶƚŚĞůĂst 7 days, defined as days in which the frequency of tests is appropriate 
(Q18) and there is no more than one reading > 11 mmol/L  
What level of control is appropriate for this patient 
Did the patient develop DKA at any time after their admission? 
SECTION C. PRESCRIBING AND DRUG MANAGEMENT ERRORS OVER LAST 7 DAYS
 
  Did the patient receive insulin at any time during the last 7 days?  Was the drug chart available for 
review? 
ŝĚĂŶǇŽĨƚŚĞĨŽůůŽǁŝŶŐŽĐĐƵƌ QKƌĂů,ǇƉŽŐůǇĐĂĞŵŝĐŐĞŶƚ ?K, ?ƉƌĞƐĐƌŝƉƚŝŽŶĞƌƌŽƌƐ Q. Insulin 
ƉƌĞƐĐƌŝƉƚŝŽŶĞƌƌŽƌƐ P Q ?/ŶƐƵůŝŶŵĂŶĂŐĞŵĞŶƚĞƌƌŽƌƐ P Q ?K,ŵĂŶĂŐĞŵĞŶƚĞƌƌŽƌƐ P Q ? ? 
SECTION D. INTRAVENOUS INSULIN INFUSIONS 
 
  Has the patient been on an insulin infusion during the last 7 days? 
Thinking of the most recent use of an insulin infusion, please complete the following: 
ƵƌĂƚŝŽŶŽĨŝŶƐƵůŝŶŝŶĨƵƐŝŽŶ Q 
Was the use of insulin infusion deemed appropriate (e.g. not eating or drinking, etc), Ws the duration of 
the infusion appropriate? If discontinued, has the transfer to sc insulin been managed appropriately, 
Total number of glucose readings in the last 24 hours on infusion, Total number of glucose readings > 
11mmol/L in the last 24 hours on infusion?, Total number of glucose readings < 4mmol/L in the last 24 
hours on infusion,
 
SECTION E. INVOLVEMENT OF THE SPECIALIST DIABETES TEAM 
 
  Was the patient previously aware that the diabetes team is available to provide support to inpatients 
with diabetes and advice to ward staff? Has the patient asked to be referred to the diabetes team, Is 
there documented evidence of the patient being seen by a member of the diabetes team? Does the 
patient wish the diabetes team to be involved in the management of their diabetes whilst in hospital? 
Should the patient have been referred to the diabetes team
 
SECTION F. GENERAL FOOT CARE
 
  Was there any documentation of a diabetic foot risk (for ulceration) assessment in the FIRST 24 hours of 
admission?  Was there any documentation of a diabetic foot risk (for ulceration) assessment AFTER the 
first 24 hours of admission? Was the patient admitted with active foot disease? Did a foot lesion (eg heel 
ulcer) arise during this admission?  Was the patient seen by a member of the foot MDT within 24 hours? 
Has there been input from the foot MDT in the last 7 days
 
ASA, American Society of Anesthesiologists classification; BMI, Body mass index; T1, type 1; T2, Type 2; DKA, 
diabetic ketoacidosis; hr, hour; OHA, oral hypoglycaemic agent; MDT, multidisciplinary team; MODY, maturity-
onset diabetes of the young 
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